<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Glob Health</journal-id><journal-id journal-id-type="iso-abbrev">J Glob Health</journal-id><journal-id journal-id-type="publisher-id">JGH</journal-id><journal-title-group><journal-title>Journal of Global Health</journal-title></journal-title-group><issn pub-type="ppub">2047-2978</issn><issn pub-type="epub">2047-2986</issn><publisher><publisher-name>International Society of Global Health</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40406989</article-id><article-id pub-id-type="pmc">PMC12100575</article-id>
<article-id pub-id-type="publisher-id">jogh-15-04152</article-id><article-id pub-id-type="doi">10.7189/jogh.15.04152</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Prognostic risk profiling in COPD using Global Initiative for Chronic Obstructive Lung Disease 2023 ABE and comorbidity assessment: evidence from a register-based COPD cohort</article-title><alt-title alt-title-type="running-head">Lin et al. Prognostic profiling in COPD: GOLD 2023 ABE and comorbidity analysis</alt-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0512-4953</contrib-id><name><surname>Lin</surname><given-names>Ching-Hsiung</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0311-8525</contrib-id><name><surname>Li</surname><given-names>Yi-Rong</given-names></name><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Cheng</surname><given-names>Shih-Lung</given-names></name><xref rid="aff6" ref-type="aff">
<sup>6</sup>
</xref><xref rid="aff7" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7528-7494</contrib-id><name><surname>Wang</surname><given-names>Hao-Chien</given-names></name><xref rid="aff8" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Lin</surname><given-names>Hen-I</given-names></name><xref rid="aff9" ref-type="aff">
<sup>9</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1203-4094</contrib-id><name><surname>Lee</surname><given-names>Kang-Yun</given-names></name><xref rid="aff10" ref-type="aff">
<sup>10</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8328-8684</contrib-id><name><surname>Chong</surname><given-names>Inn-Wen</given-names></name><xref rid="aff11" ref-type="aff">
<sup>11</sup>
</xref><xref rid="aff12" ref-type="aff">
<sup>12</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Chan</surname><given-names>Po-Chiang</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Huan-Wei</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5664-9392</contrib-id><name><surname>Yu</surname><given-names>Chong-Jen</given-names></name><xref rid="aff13" ref-type="aff">
<sup>13</sup>
</xref></contrib><aff id="aff1"><label>1</label>Division of Chest Medicine, Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan</aff><aff id="aff2"><label>2</label>Institute of Genomics and Bioinformatics, National Chung Hsing University, Taichung, Taiwan</aff><aff id="aff3"><label>3</label>PhD Program in Translational Medicine, National Chung Hsing University, Taichung, Taiwan</aff><aff id="aff4"><label>4</label>Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan</aff><aff id="aff5"><label>5</label>Thoracic Medicine Research Centre, Changhua Christian Hospital, Changhua, Taiwan</aff><aff id="aff6"><label>6</label>Department of Internal Medicine, Far Eastern Memorial Hospital, Taipei, Taiwan</aff><aff id="aff7"><label>7</label>Department of Chemical Engineering and Materials Science, Yuan Ze University, Taoyuan, Taiwan</aff><aff id="aff8"><label>8</label>Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan</aff><aff id="aff9"><label>9</label>Department of Internal Medicine, Cardinal Tien Hospital, New Taipei City, Taiwan</aff><aff id="aff10"><label>10</label>Division of Pulmonary Medicine, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan</aff><aff id="aff11"><label>11</label>Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan</aff><aff id="aff12"><label>12</label>Department of Biological Science and Technology, National Yang Ming Chiao Tung University, Hsinchu, Taiwan</aff><aff id="aff13"><label>13</label>Department of Internal Medicine, National Taiwan University Hospital, Hsin-Chu Branch, Hsinchu County, Taiwan</aff></contrib-group><author-notes><corresp id="cor1"><bold>Correspondence to:</bold>&#x02028;Ching-Hsiung Lin&#x02028;Department of Internal Medicine, Division of Chest Medicine, Changhua Christian Hospital&#x02028;135 Nanhsiao Street, Changhua&#x02028;Taiwan&#x02028;<email xlink:href="47822@cch.org.tw">47822@cch.org.tw</email>&#x02028;Chong-Jen Yu&#x02028;Department of Internal Medicine, National Taiwan University Hospital, Hsin-Chu Branch&#x02028;No. 2, Sec 1, Shengui Road., Zubei City&#x02028;Taiwan&#x02028;<email xlink:href="jefferycjyu@ntu.edu.tw">jefferycjyu@ntu.edu.tw</email></corresp></author-notes><pub-date publication-format="electronic" date-type="pub"><day>23</day><month>5</month><year>2025</year></pub-date><pub-date publication-format="electronic" date-type="collection"><year>2025</year></pub-date><volume>15</volume><elocation-id>04152</elocation-id><permissions><copyright-statement>Copyright &#x000a9; 2025 by the Journal of Global Health. All rights reserved.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This work is licensed under a Creative Commons Attribution 4.0 International License.</license-p></license></permissions><abstract><sec><title>Background</title><p>While the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 ABE classification system guides initial chronic obstructive pulmonary disease (COPD) treatment, patient heterogeneity and comorbidities complicate management. We investigated how the GOLD 2023 ABE classification and aligned comorbidity profiles affect patient outcomes in real-world Asian populations with COPD.</p></sec><sec><title>Methods</title><p>We conducted a register-based cohort study of 38&#x02009;928 patients from multiple institutions across Taiwan (from April 2017 to December 2021). We classified patients by GOLD 2023 ABE categories. Data included demographics, Charlson comorbidity index (CCI)-defined comorbidities, treatment, symptoms, questionnaires, spirometry, and outcomes.</p></sec><sec><title>Results</title><p>Among COPD patients, 89.2% were males, and the median age was 71 years. Groups A comprised 30.2%, group B 46.4%, and group E 23.5% of patients. Among these, 28.3% of group A patients used inhaled corticosteroid-containing inhalers. Group E had the highest rates of GOLD 4 airway obstruction (11.8%), CCI score &#x02265;4 (15.6%), and five-year mortality rate (22.6%). Group E demonstrated the highest risk of all-cause mortality (hazard ratio (HR)&#x02009;=&#x02009;1.727; 95% confidence interval (CI)&#x02009;=&#x02009;1.605&#x02013;1.858) and moderate-to-severe exacerbation (HR&#x02009;=&#x02009;2.127; 95% CI&#x02009;=&#x02009;1.942&#x02013;2.330) <italic>vs.</italic> group A. Key comorbidities, acute myocardial infarction (HR&#x02009;=&#x02009;1.257; 95% CI&#x02009;=&#x02009;1.057&#x02013;1.430), congestive heart failure (HR&#x02009;=&#x02009;1.836; 95% CI&#x02009;=&#x02009;1.707&#x02013;1.909), and pulmonary disease (HR&#x02009;=&#x02009;1.071; 95% CI&#x02009;=&#x02009;1.011&#x02013;1.129), were associated with higher mortality. Acute myocardial infarction (HR&#x02009;=&#x02009;1.251; 95% CI&#x02009;=&#x02009;1.031&#x02013;1.444), congestive heart failure (HR&#x02009;=&#x02009;1.193; 95% CI&#x02009;=&#x02009;1.089&#x02013;1.285), and pulmonary disease (HR&#x02009;=&#x02009;1.491; 95% CI&#x02009;=&#x02009;1.405&#x02013;1.550) were also associated with higher exacerbations, with patterns varying across GOLD groups.</p></sec><sec><title>Conclusions</title><p>In this large registry-based cohort, group E patients demonstrated the highest mortality and exacerbation risks. Cardiovascular and pulmonary comorbidities increased adverse outcome risks across all GOLD categories. Systematic comorbidity screening should be integrated into routine COPD care. Findings support personalised treatment approaches based on GOLD classification and comorbidity profiles.</p></sec></abstract><counts><fig-count count="3"/><table-count count="1"/><equation-count count="0"/><ref-count count="72"/><page-count count="18"/></counts></article-meta></front><body><p>Chronic obstructive pulmonary disease (COPD) is a heterogeneous and multisystemic lung condition that poses a significant global health burden as the third leading cause of death worldwide [<xref rid="R1" ref-type="bibr">1</xref>&#x02013;<xref rid="R3" ref-type="bibr">3</xref>]. It is characterised by persistent airflow limitation and chronic respiratory symptoms caused by abnormalities in the airways and/or alveoli, leading to progressive airflow obstruction [<xref rid="R4" ref-type="bibr">4</xref>,<xref rid="R5" ref-type="bibr">5</xref>]. COPD significantly impairs patients&#x02019; quality of life and is frequently accompanied by multimorbidity, including other chronic conditions linked through shared risk factors such as smoking, ageing, and environmental exposures [<xref rid="R6" ref-type="bibr">6</xref>,<xref rid="R7" ref-type="bibr">7</xref>]. The characteristics and prognosis of COPD patients are continually evolving due to demographic shifts, such as an ageing population, and advancements in treatment strategies. Thus, understanding the most current baseline data and prognosis of COPD provides crucial insights into disease behaviour and supports precision management strategies.</p><p>The Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy provides guidelines for the prevention, diagnosis, treatment, and follow-up of COPD patients [<xref rid="R8" ref-type="bibr">8</xref>]. The COPD classification system has evolved significantly through several iterations. GOLD 2011 introduced a multidimensional ABCD system combining spirometry, symptoms, and exacerbation risk, but faced criticism for its complexity and potential for misclassification [<xref rid="R9" ref-type="bibr">9</xref>,<xref rid="R10" ref-type="bibr">10</xref>]. GOLD 2017 simplified assessment by removing spirometric thresholds from the ABCD grouping, focusing instead on symptoms and exacerbation history. Although previous studies have demonstrated that the GOLD ABCD grade effectively predicts future exacerbations and mortality in COPD patients, growing evidence indicates that exacerbation history remains the strongest predictor of future exacerbation risk and death [<xref rid="R11" ref-type="bibr">11</xref>,<xref rid="R12" ref-type="bibr">12</xref>]. The 2023 update further refined the classification system by introducing three subgroups A, B, and E, with a significant change merging the high-risk groups C and D into a single category E, defined solely by exacerbation history [<xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R13" ref-type="bibr">13</xref>]. This change simplifies clinical assessment and optimises treatment recommendations. While these classifications were originally designed to guide treatment, they have been widely adopted for prognostic predictions [<xref rid="R14" ref-type="bibr">14</xref>&#x02013;<xref rid="R16" ref-type="bibr">16</xref>], with previous studies revealing higher mortality and exacerbation rates in groups B and D [<xref rid="R15" ref-type="bibr">15</xref>,<xref rid="R16" ref-type="bibr">16</xref>]. However, despite these modifications, research in a recent study revealed that the GOLD 2023 classification based on ABE groups did not predict mortality better than the earlier 2017 ABCD classifications [<xref rid="R17" ref-type="bibr">17</xref>].</p><p>Comorbidities significantly influence COPD prognosis and are highly prevalent among COPD patients. These concurrent conditions &#x02013; including cardiovascular diseases, metabolic disorders, mental health issues, musculoskeletal disorders, and cancer &#x02013; share common risk factors and systemic mechanisms with COPD [<xref rid="R6" ref-type="bibr">6</xref>,<xref rid="R7" ref-type="bibr">7</xref>]. Their presence increases the frequency of exacerbations, hospitalisations, and mortality risk [<xref rid="R18" ref-type="bibr">18</xref>&#x02013;<xref rid="R20" ref-type="bibr">20</xref>], as measured by validated indices such as the Charlson comorbidity index (CCI), body-mass index, obstruction, dyspnea, and exercise (BODE), and COPD-specific comorbidity test indices [<xref rid="R19" ref-type="bibr">19</xref>,<xref rid="R21" ref-type="bibr">21</xref>]. The complex interplay between COPD and comorbidities contributes to increased health care utilisation and reduced quality of life [<xref rid="R22" ref-type="bibr">22</xref>,<xref rid="R23" ref-type="bibr">23</xref>]. Effective management of COPD, therefore, requires an integrated approach that addresses both the primary respiratory condition and its associated comorbidities to improve patient outcomes. As global populations age, particularly in East Asian countries like Taiwan [<xref rid="R24" ref-type="bibr">24</xref>,<xref rid="R25" ref-type="bibr">25</xref>], COPD patients increasingly present with multiple comorbidities, including cardiovascular diseases, diabetes, and depression. This evolving patient profile necessitates comprehensive disease management strategies that extend beyond respiratory care, highlighting the importance of integrated approaches. However, large-scale real-world data on the characteristics, comorbidities, and prognosis of COPD under the GOLD 2023 ABE classification remain limited, particularly in ageing populations with increasing comorbidity burdens.</p><p>Real-world data offers a cost-effective, comprehensive source of patient insights, improving research generalisability and enabling the identification of long-term trends. While these data provide valuable opportunities to generate evidence on drug treatment effects in populations typically excluded from clinical trials, there remains a critical gap in validated, rigorous methodological approaches for conducting such analyses effectively [<xref rid="R26" ref-type="bibr">26</xref>&#x02013;<xref rid="R28" ref-type="bibr">28</xref>]. Patient registries serve as a vital source of real-world data and real-world evidence. They can be precisely designed according to specific requirements, serving as a significant medium for observing actual clinical practices. With established quality standards and evaluation criteria, patient registries provide a solid foundation for research and development in health care, making them the new gold standard for real-world study [<xref rid="R29" ref-type="bibr">29</xref>&#x02013;<xref rid="R31" ref-type="bibr">31</xref>]. Despite the growing use of real-world data for COPD research, including registry data, over the past decades, large-scale longitudinal registry data sets that align their data elements with existing COPD-specific guidelines remain scarce.</p><p>Taiwan COPD patient registry, part of the ongoing COPD integrated care initiative known as the Taiwan COPD Pay-for-Performance Program, is a five-year longitudinal data set designed in alignment with COPD-specific guidelines. In this study, we aimed to use data from the Taiwan COPD patient registry to investigate the baseline characteristics, comorbidity profiles, and long-term prognosis of spirometry-confirmed COPD patients enrolled in a guideline-based care program, classified according to GOLD 2023 classification.</p><sec sec-type="methods"><title>METHODS</title><sec><title>Study design and data source</title><p>We conducted this retrospective study using a Taiwan COPD national registry database, which is part of an ongoing longitudinal project known as Taiwan COPD pay-for-performance (P4P) and launched by the Taiwan National Health Insurance on 1 April 2017, aiming to provide an integrated disease management program for COPD patients. We used the Taiwan National Health Insurance claim database to gather demographic information, diagnostic codes, and health insurance claims data for patients enrolled in the Taiwan COPD P4P program. Between 1 April 2017 and 31 December 2021. This cohort consisted of approximately 40&#x02009;000 participants from 216 primary and secondary care practices distributed throughout Taiwan, including medical centres, regional hospitals, district hospitals, and primary care clinics across diverse geographic regions. This multi-level health care facility recruitment approach ensures broad population representation beyond single-institution limitations. Moreover, the program encompasses multiple medical specialities, including family medicine, pulmonology and critical care, internal medicine, paediatrics, otolaryngology, and neurology, ensuring diverse clinical perspectives in patient management. All participating health care providers received standardised training on the Taiwan COPD P4P program and followed established Taiwan&#x02019;s COPD guidelines with a disease management protocol.</p><p>We conducted data collection through a unified, nationwide virtual private network system with structured fields for case information registration, enhancing data consistency and minimising documentation variability. The P4P program also incorporates a systematic referral network allowing for upward referral of exacerbated cases and downward referral of stabilised patients, facilitating appropriate care levels regardless of initial recruitment site. The full details of the protocol of Taiwan&#x02019;s COPD P4P program have been previously published. We adhered to the principles outlined in the Declaration of Helsinki, and the Institutional Review Board of Changhua Christian Hospital approved the study (approval number 230512). Informed consent was waived due to the retrospective design of the study. We conducted all procedures in compliance with relevant ethical guidelines and regulations. The data used in the study were de-identified, and researchers strictly followed Taiwan&#x02019;s computer-processed personal data protection law and related privacy regulations.</p></sec><sec><title>Participants and measurement method</title><p>Patients diagnosed with COPD (International Classification of Diseases (ICD-10) codes J41&#x02013;J44) within the past 90 days at the same health care institution and confirmed by spirometry (forced expiratory volume in one second (FEV<sub>1</sub>)/forced vital capacity (FVC)&#x0003c;0.7) were eligible for inclusion. To qualify, we required patients to have at least two visits to the institution, with COPD documented as the primary diagnosis during the recruitment visit. We excluded patients with missing baseline data, including demographic information, spirometry results, the COPD assessment test (CAT) scores, and modified British Medical Research Council (mMRC) grades. All patients were classified according to GOLD 2023 guidelines.</p></sec><sec><title>Spirometric measurements</title><p>We performed all spirometry according to the American Thoracic Society and European Respiratory Society standardisation guidelines. We collected FEV<sub>1</sub>, FVC, and their predicted values with appropriate adjustments for age, gender, body height, weight, and race [<xref rid="R32" ref-type="bibr">32</xref>]. These standardised procedures guarantee the reproducibility and accuracy of our spirometric data.</p></sec><sec><title>Patient-reported outcomes</title><p>We measured patient-reported outcomes by the mMRC dyspnoea scale and the CAT. mMRC is a well-established five-point scale (zero to four) that assesses breathlessness during physical activities [<xref rid="R33" ref-type="bibr">33</xref>]. CAT is a comprehensive eight-question instrument (on a one to five point scale) that evaluates the overall impact of COPD on patients, including symptoms such as cough, sputum, breathlessness, chest tightness, and effects on confidence, activity, sleep, and energy levels [<xref rid="R34" ref-type="bibr">34</xref>]. Both the mMRC and CAT are validated questionnaires recommended by the GOLD guidelines for classifying COPD risk groups. Their reliability and validity have been established through extensive previous research [<xref rid="R35" ref-type="bibr">35</xref>,<xref rid="R36" ref-type="bibr">36</xref>]. In our previous study, CAT and mMRC have been found to provide individual benefits in the evaluation of clinical symptoms, comorbidities, and medical resource utilisation for emergency department visits, hospitalisation, and intensive care unit admission in Taiwanese COPD patients [<xref rid="R37" ref-type="bibr">37</xref>]. Given their proven reliability and clinical utility, we selected these validated measures to appropriately assess patient-reported outcomes in our research.</p></sec><sec><title>Data collection and outcomes</title><p>Demographic data included age, gender, body mass index (BMI), and smoking status. Baseline clinical characteristics encompassed post-bronchodilator spirometry results, CCI score, severity of airflow limitation, mMRC grade, CAT score, acute exacerbation history, GOLD risk group classification, wheezing, family history of COPD, and maintenance inhaler therapy. We determined airflow limitation severity and GOLD risk group classifications according to the 2023 GOLD guidelines. We categorised airflow limitation as follows: mild (FEV<sub>1</sub>&#x02265;80% predicted), moderate (50%&#x02264;FEV<sub>1</sub>&#x0003c;80% predicted), severe (30%&#x02264;FEV<sub>1</sub>&#x0003c;50% predicted), and very severe (FEV<sub>1</sub>&#x0003c;30% predicted). We used the CCI to assess baseline comorbidity burden. We defined comorbidities as present if the relevant code appeared at least once in admission records or three times in outpatient department diagnosis codes [<xref rid="R38" ref-type="bibr">38</xref>]. Moreover, we applied the well-validated ICD coding algorithm based on the claims-based, disease-specific refinements, matching translation to ICD-10, flexibility (CDMF) to allow use as a chart review instrument CCI scheme described by Glasheen et al [<xref rid="R39" ref-type="bibr">39</xref>]. We excluded from the analysis cases with incomplete demographic data, baseline spirometry measurements, or CAT/mMRC scores. As clinical covariates were fully accessible through the electronic medical record system for all admitted patients, we employed a complete case analysis approach, ensuring that we included in the final analysis only patients with complete data across all variables. The primary outcome was all-cause mortality, while the secondary outcome was moderate-to-severe exacerbations. Moderate exacerbations were defined as prescriptions of short-acting bronchodilators and oral corticosteroids (anatomical therapeutic chemical codes H02AB and R03CC) combined with a diagnosis code for COPD (ICD-10 codes J41&#x02013;J44) on the same day, ensuring the medication was prescribed specifically for COPD exacerbation [<xref rid="R40" ref-type="bibr">40</xref>]. Severe exacerbations were identified through emergency department visits and hospital admissions lasting more than two consecutive days with a primary diagnosis of COPD [<xref rid="R41" ref-type="bibr">41</xref>]. We obtained mortality data from National Health Insurance disenrollment records marked as death with recorded dates.</p></sec><sec><title>Statistical analysis</title><p>We reported descriptive data as medians (MD) and interquartile ranges (IQR) or percentages, as appropriate. We performed comparisons between groups for descriptive summaries using &#x003c7;<sup>2</sup> tests for categorical variables and analysis of variance for continuous variables. Given the concern over the three, rather than two groups in our study, we used inverse probability weighting (propensity score) for each patient via logistic regression to reduce the confounding effects due to the imbalances in the distribution of baseline characteristics. A multivariable Cox proportional hazards model was used to establish independent predictors of all-cause mortality and moderate-to-severe exacerbation. For moderate-to-severe exacerbations, we employed competing risk analysis to account for death as a competing event. We presented results as adjusted hazard ratios (HRs) with corresponding confidence intervals (CIs). For data management, analysis, and visualisation, we used SAS, version 9.4 (SAS Institute Inc., Cary, North Carolina, USA) or <italic>R</italic>, version 4.1.0 (R Core Team, Vienna, Austria). We considered a two-tailed <italic>P</italic>-value &#x0003c;0.05 statistically significant in all analyses.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><sec><title>Baseline characteristics and clinical outcomes of COPD patients by GOLD 2023 classification</title><p>We analysed 38&#x02009;928 COPD patients categorised by GOLD 2023, following their reclassification from the previous GOLD 2017 system. The analysis showed that patients formerly in GOLD 2017 group C (n&#x02009;=&#x02009;2977, 7.6%) and group D (n&#x02009;=&#x02009;6154, 15.8%) were reclassified into the new GOLD 2023 group E (n&#x02009;=&#x02009;9131, 23.5%) (Figure S1 in the <xref rid="S1" ref-type="supplementary-material"><bold>Online Supplementary Document</bold></xref>). Age was MD&#x02009;=&#x02009;71 years, with group A being younger, and groups B and E older. Most patients were predominantly male. Smoking history varied significantly, with group E having the highest proportion of former smokers (59.4%). Pulmonary functions, including FEV<sub>1</sub>, the percentage predicted forced expiratory volume in one second (FEV<sub>1%</sub> predicted) and FEV<sub>1</sub>/FVC ratios, were highest in group A and lowest in group E. Airflow limitation was primarily moderate, with group E having the highest proportion of severe obstruction (stage four). Group E also showed a higher symptom burden (mMRC and CAT scores), proportion of wheezing and more severe comorbidities compared to other groups.</p><p>The proportion of patients without a prescription decreased across all groups, with group A having the highest rate. Among all groups, the use of long-acting muscarinic antagonists (LAMAs) was higher compared to long-acting beta-agonists (LABAs). LABA/LAMA combination was the most frequently prescribed in the overall cohort (43.4%) as well as each group (39.0% in group A, 47.4% in group B, and 39.6% in group E), whereas the triple inhaler was most commonly used in group E (34.3%). The proportion of patients using dual inhalers increased progressively across groups A (66.5%), B (76.3%), and E (86.8%). Furthermore, 28.3% of group A patients using inhaled corticosteroid-containing inhalers. The mortality rate over five years was 14.3% of overall patients, highest in group E (22.6%) and lowest in group A (8.4%) (<xref rid="T1" ref-type="table"><bold>Table 1</bold></xref>).</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Baseline demographic and outcome of patients with COPD by GOLD 2023 classification*</p></caption><table frame="hsides" rules="groups"><col width="164" span="1"/><col width="98" span="1"/><col width="107" span="1"/><col width="107" span="1"/><col width="107" span="1"/><col width="107" span="1"/><thead><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Demographics</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">All patients (n&#x02009;=&#x02009;38&#x02009;928)</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Group A (n&#x02009;=&#x02009;11&#x02009;741)</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Group B (n&#x02009;=&#x02009;18&#x02009;056)</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Group E (n&#x02009;=&#x02009;9131)</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Age in years, MD (IQR)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">71 (64&#x02013;78)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">69 (63&#x02013;77)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">72 (64&#x02013;79)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">72 (64&#x02013;79)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.0001<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Age category in years<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">
<italic>&#x02264;50</italic>
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">987 (2.5)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">371 (3.2)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">411 (2.3)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">205 (2.2)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">
<italic>51&#x02013;60</italic>
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">4639 (11.9)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1609 (13.7)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2016 (11.2)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1014 (11.1)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">
<italic>61&#x02013;70</italic>
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">12&#x02009;104 (31.1)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">4057 (34.6)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">5317 (29.4)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2730 (29.9)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">
<italic>71&#x02013;80</italic>
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">12&#x02009;771 (32.8)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3768 (32.1)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">6069 (33.6)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2934 (32.1)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">
<italic>&#x0003e;80</italic>
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">8427 (21.6)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1936 (16.5)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">4243 (23.5)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2248 (24.6)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Male<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">34&#x02009;722 (89.2)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">10&#x02009;506 (89.5)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">16&#x02009;074 (89)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">8142 (89.2)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.0001<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">BMI in kg/m<sup>2</sup>, MD (IQR)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">23.7 (21.2&#x02013;26.4)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">23.9 (21.5&#x02013;26.4)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">23.8 (21.2&#x02013;26.5)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">23.3 (20.6&#x02013;26.2)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.0001<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">BMI category in kg/m<sup>2</sup><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">
<italic>&#x0003c;18.5</italic>
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">3005 (7.7)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">698 (5.9)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1329 (7.4)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">978 (10.7)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">
<italic>18.5&#x02013;24</italic>
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">17&#x02009;470 (44.9)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">5255 (44.8)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">8026 (44.5)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">4189 (45.9)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">
<italic>&#x02265;24</italic>
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">18&#x02009;453 (47.4)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">5788 (49.3)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">8701 (48.2)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3964 (43.4)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Smoking status<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">
<italic>Never</italic>
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">6202 (15.9)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2016 (17.2)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2851 (15.8)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1335 (14.6)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">
<italic>Former</italic>
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">21&#x02009;255 (54.6)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">6124 (52.2)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">9704 (53.7)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">5427 (59.4)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">
<italic>Current</italic>
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">11&#x02009;471 (29.5)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3601 (30.7)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">5501 (30.5)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2369 (25.9)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">COPD family history<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">
<italic>Yes</italic>
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">3120 (8)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">832 (7.1)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1394 (7.7)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">894 (9.8)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">
<italic>No</italic>
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">35&#x02009;808 (92)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">10&#x02009;909 (92.9)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">16&#x02009;662 (92.3)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">8237 (90.2)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Pulmonary function test, MD (IQR)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">
<italic>Post-BD FEV<sub>1</sub>, L</italic>
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">60.0 (50.4&#x02013;67.0)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">66.0 (50.0&#x02013;81.0)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">59.0 (45.0&#x02013;74.0)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">47.0 (35.0&#x02013;63.0)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.0001<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">
<italic>Post-BD FEV<sub>1</sub>, % predicted</italic>
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">1.4 (1.03&#x02013;1.85)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.56 (1.15&#x02013;2.01)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.32 (0.97&#x02013;1.74)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.06 (0.78&#x02013;1.43)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.0001<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">
<italic>Post-BD FEV<sub>1</sub>/FVC, %</italic>
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">62.0 (46.7&#x02013;78.0)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">62.8 (54.4&#x02013;68.3)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">59.8 (50.4&#x02013;66.2)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">55 (45.2&#x02013;63.8)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.0001<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">mMRC dyspnea scale, MD (IQR)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2 (1&#x02013;2)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1 (0&#x02013;1)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2 (1&#x02013;2)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2 (1&#x02013;3)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.0001<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">mMRC category<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">
<italic>&#x0003c;2</italic>
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">18&#x02009;744 (48.2)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">10&#x02009;866 (92.5)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">5367 (29.7)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2511 (27.5)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">
<italic>&#x02265;2</italic>
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">20&#x02009;184 (51.8)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">875 (7.5)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">12&#x02009;689 (70.3)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">6620 (72.5)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">CAT score, MD (IQR)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">10 (6&#x02013;16)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">5 (3&#x02013;8)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">12 (10&#x02013;17)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">13 (9&#x02013;20)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.0001<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">CAT category<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">
<italic>1&#x02013;10</italic>
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">20&#x02009;189 (51.9)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">10&#x02009;762 (91.7)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">6207 (34.4)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3220 (35.3)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">
<italic>11&#x02013;20</italic>
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">14&#x02009;650 (37.6)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">754 (6.4)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">9854 (54.6)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">4042 (44.3)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">
<italic>21&#x02013;30</italic>
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">3742 (9.6)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">194 (1.7)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1888 (10.5)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1660 (18.2)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">
<italic>31&#x02013;40</italic>
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">347 (0.9)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">31 (0.3)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">107 (0.6)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">209 (2.3)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Wheezing<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">
<italic>Yes</italic>
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">7378 (19)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1043 (8.9)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3593 (19.9)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2742 (30)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">
<italic>No</italic>
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">31&#x02009;550 (81)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">10&#x02009;698 (91.1)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">14&#x02009;463 (80.1)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">6389 (70)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">CCI, MD (IQR)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1 (0&#x02013;2)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1 (0&#x02013;2)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1 (0&#x02013;2)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1 (0&#x02013;3)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.0001<hr/></td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">CCI category<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">
<italic>0</italic>
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">12&#x02009;149 (31.2)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">4057 (34.6)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">5593 (31)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2499 (27.4)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">
<italic>1&#x02013;3</italic>
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">21&#x02009;265 (54.6)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">6230 (53.1)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">9830 (54.4)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">5205 (57)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">
<italic>&#x02265;4</italic>
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">5514 (14.2)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1454 (12.4)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2633 (14.6)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1427 (15.6)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Exacerbation history in the prior year<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">
<italic>&#x0003c;2</italic>
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">34&#x02009;150 (87.7)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">11&#x02009;566 (98.5)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">17&#x02009;470 (96.8)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">5114 (56)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">
<italic>&#x02265;2</italic>
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">4778 (12.3)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">175 (1.5)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">586 (3.2)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">4017 (44)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Airflow limitation severity level<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">
<italic>I</italic>
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">8846 (22.7)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3776 (32.2)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3977 (22)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1093 (12)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">
<italic>II</italic>
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">18&#x02009;520 (47.6)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">5681 (48.4)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">9291 (51.5)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3548 (38.9)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">
<italic>III</italic>
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">9254 (23.8)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1918 (16.3)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3921 (21.7)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3415 (37.4)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">
<italic>IV</italic>
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">2308 (5.9)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">366 (3.1)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">867 (4.8)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1075 (11.8)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Maintenance inhaler treatment<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">
<italic>None</italic>
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">1564 (4.0)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">753 (6.4)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">556 (3.1)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">255 (2.8)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">
<italic>ICS</italic>
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">192 (0.5)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">89 (0.8)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">52 (0.3)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">51 (0.6)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">
<italic>LABA</italic>
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">807 (2.1)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">333 (2.8)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">407 (2.3)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">67 (0.7)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">
<italic>LAMA</italic>
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">6861 (17.6)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2762 (23.5)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3269 (18.1)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">830 (9.1)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">
<italic>LABA&#x02009;+&#x02009;ICS or LABA/ICS</italic>
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">5107 (13.1)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1617 (13.8)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2312 (12.8)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1178 (12.9)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">
<italic>LABA&#x02009;+&#x02009;LAMA or LABA/LAMA</italic>
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">16&#x02009;752 (43.0)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">4574 (39)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">8559 (47.4)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3619 (39.6)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">
<italic>Triple&#x02020;</italic>
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">7645 (19.6)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1613 (13.7)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2901 (16.1)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3131 (34.3)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Five-year cumulative all-cause mortality rate<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">
<italic>Yes</italic>
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">5578 (14.3)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">988 (8.4)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2528 (14)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2062 (22.6)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">
<italic>No</italic>
</td><td valign="top" align="center" rowspan="1" colspan="1">33&#x02009;350 (85.7)</td><td valign="top" align="center" rowspan="1" colspan="1">10&#x02009;753 (91.6)</td><td valign="top" align="center" rowspan="1" colspan="1">15&#x02009;528 (86)</td><td valign="top" align="center" rowspan="1" colspan="1">7069 (77.4)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><p>BMI &#x02013; body mass index, CAT &#x02013; COPD assessment test, CCI &#x02013; Charlson comorbidity index, COPD &#x02013; chronic obstruction pulmonary disease, FEV1 &#x02013; forced expiratory volume in the first-second, FEV1%pred &#x02013; percentage predicted the forced expiratory volume in one second, FVC &#x02013; forced vital capacity, ICS &#x02013; inhaled corticosteroid, IQR &#x02013; interquartile range, LABA &#x02013; long-acting &#x003b2;2-agonist, LAMA &#x02013; long-acting muscarinic antagonist, MD &#x02013; median, mMRC &#x02013; modified Medical Research Council</p><p>*Presented as n (%) unless specified otherwise.</p><p>&#x02020;Presented as LABA+LAMA+ICS or LABA/LAMA+ICS or LABA/LAMA/ICS.</p></table-wrap-foot></table-wrap></sec><sec><title>Survival analysis and risk factors for all-cause mortality and moderate-to-severe exacerbation across GOLD 2023 classification</title><p>The results demonstrate significant differences in outcomes across the risk groups (A, B, and E), with a notable severity gradient. Patients in group E experienced the lowest survival rate and the highest exacerbation rate when compared to Group A (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001), suggesting a more pronounced disease burden in these patients. The HRs for five-year all-cause mortality were 1.3 times higher in group B (HR&#x02009;=&#x02009;1.332; 95% CI&#x02009;=&#x02009;1.244&#x02013;1.426, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001) and 1.7 times higher in group E (HR&#x02009;=&#x02009;1.727; 95% CI&#x02009;=&#x02009;1.605&#x02013;1.858, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001), relative to group A. This clearly highlights the increasing risk of death with worsening classification (<xref rid="F1" ref-type="fig"><bold>Figure 1</bold></xref>, Panel A).</p><fig position="float" id="F1" fig-type="figure"><label>Figure 1</label><caption><p>Kaplan-Meier curves and forest plot of all-cause mortality. <bold>Panel A.</bold> All-cause mortality by GOLD 2023 classification. <bold>Panel B.</bold> All-cause mortality by GOLD 2017 classification. <bold>Panel C.</bold> Risk factor of all-cause mortality.</p></caption><graphic xlink:href="jogh-15-04152-F1" position="float"/></fig><p>Interestingly, by applying the classification of GOLD 2017, the outcomes for patients in group B were found to be quite similar to those in group C, with their Kaplan-Meier curves nearly overlapping. Moreover, there was no significant difference in HRs for both all-cause mortality between groups B and C under GOLD 2017. On the other hand, a significant distinction was noted between groups C and D under GOLD 2017, with group D having significantly worse outcomes in all-cause mortality. The HRs for group D were notably higher, indicating that patients in this group faced a markedly greater disease burden (<xref rid="F1" ref-type="fig"><bold>Figure 1</bold></xref>, Panel B). The multivariable Cox proportional hazards regression results analysis indicated that the risk factors for five-year all-cause mortality included age &#x0003e;80 years, gender, smoking, wheezing, a higher CCI score, lower BMI, and worse airflow obstruction. A family history of COPD had a significantly negative association with five-year all-cause mortality (<xref rid="F1" ref-type="fig"><bold>Figure 1</bold></xref>, Panel C). For moderate-to-severe exacerbation, the HRs for moderate-to-severe exacerbations were found to be 1.4 times higher in group B (HR&#x02009;=&#x02009;1.407; 95% CI&#x02009;=&#x02009;1.292&#x02013;1.532, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001) and 2.0 times higher in group E (HR&#x02009;=&#x02009;2.127; 95% CI&#x02009;=&#x02009;1.942&#x02013;2.330, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001) compared to group A (<xref rid="F2" ref-type="fig"><bold>Figure 2</bold></xref>, Panel A). Age &#x0003e;80 years old, gender, smoking, family history of COPD, wheezing, a higher CCI score, lower BMI, and GOLD 4 airflow obstruction were significant risk factors for moderate-to-severe acute exacerbation. The patterns were similar across GOLD 2023 group ABE categories. (<xref rid="F2" ref-type="fig"><bold>Figure 2</bold></xref>, Panels B&#x02013;C; Figure S2 in the <xref rid="S1" ref-type="supplementary-material"><bold>Online Supplementary Document</bold></xref>).</p><fig position="float" id="F2" fig-type="figure"><label>Figure 2</label><caption><p>Kaplan-Meier curves and forest plot of moderate-to-severe exacerbation. <bold>Panel A.</bold> All-cause mortality by GOLD 2023 classification. <bold>Panel B.</bold> All-cause mortality by GOLD 2017 classification. <bold>Panel C.</bold> Risk factor of moderate-to-severe exacerbation</p></caption><graphic xlink:href="jogh-15-04152-F2" position="float"/></fig></sec><sec><title>Distribution of comorbidities in COPD patients</title><p>The analysis demonstrated significant variability in comorbidity prevalence between groups. Group E exhibited the highest percentage of patients with each comorbidity, while group A had the lowest burden of comorbid diseases. Among all groups, the three most prevalent CCI-defined comorbidities of COPD were pulmonary disease (PD), peptic ulcer disease (PUD), diabetes mellitus (DM) (<xref rid="F3" ref-type="fig"><bold>Figure 3</bold></xref>, Panel A). To gain a deeper understanding of the co-occurrence patterns of CCI-defined disease in COPD, we performed a comprehensive analysis on the frequency of all potential comorbidity pairs (<xref rid="F3" ref-type="fig"><bold>Figure 3</bold></xref>, Panel B). The findings revealed that most disease pairs have a co-occurrence frequency below 1.0%. Six diseases exhibited a co-occurrence rate exceeding 1.0% with other conditions, including congestive heart failure (CHF), PD, PUD, DM, renal disease (RED), and cancer/metastasis. The most prevalent co-occurrence was between PD and PUD (4.5%), followed by PD and DM (4.4%), as well as PD and CHF (3.1%). These patterns were consistently observed across all GOLD classification groups, reinforcing the robustness of these findings. Additionally, the chord diagram visualises a complex network of interactions among CCI-defined comorbidity (<xref rid="F3" ref-type="fig"><bold>Figure 3</bold></xref>, Panel C).</p><fig position="float" id="F3" fig-type="figure"><label>Figure 3</label><caption><p>Distribution of the percentage of patients for each of the CCI diseases and the relationship between comorbidities, all-cause mortality, or moderate-to-severe exacerbations. <bold>Panel A.</bold> Distribution of the percentage of patients. <bold>Panel B.</bold> Percentage of patients diagnosed with two CCI diseases. The higher the percentage, the darker the colour of the heatmap cells. Gold, blue, green, and red cell colours correspond to all patients, GOLD A, GOLD B, GOLD E, respectively. <bold>Panel C.</bold> Chord diagram of the correlation between diseases. The length of each arc of the circle perimeter is proportional to the number of patients with the corresponding disease. <bold>Panel D.</bold> Forest plot of the relationship between comorbidities and all-cause mortality in patients with COPD. <bold>Panel E.</bold> Forest plot of the relationship between comorbidities and moderate-to-severe exacerbation in patients with COPD.</p></caption><graphic xlink:href="jogh-15-04152-F3" position="float"/></fig></sec><sec><title>Association between individual comorbidities and all-cause mortality among COPD</title><p>The forest plots illustrate specific mortality risks associated with comorbidities in COPD patients. The overall analysis (<xref rid="F3" ref-type="fig"><bold>Figure 3</bold></xref>, Panel D) revealed HRs for several key conditions: cancer/metastasis (HR&#x02009;=&#x02009;2.306; 95% CI&#x02009;=&#x02009;2.135&#x02013;2.383), CHF (HR&#x02009;=&#x02009;1.836; 95% CI&#x02009;=&#x02009;1.707&#x02013;1.909), dementia (HR&#x02009;=&#x02009;1.891; 95% CI&#x02009;=&#x02009;1.68&#x02013;2.01), acute myocardial infarction (AMI) (HR&#x02009;=&#x02009;1.257; 95% CI&#x02009;=&#x02009;1.057&#x02013;1.43), and PD (HR&#x02009;=&#x02009;1.071; 95% CI&#x02009;=&#x02009;1.011&#x02013;1.129). In GOLD A patients (Figure S4, Panel A in the <xref rid="S1" ref-type="supplementary-material"><bold>Online Supplementary Document</bold></xref>), the HRs were: cancer/metastasis (HR&#x02009;=&#x02009;2.344; 95% CI&#x02009;=&#x02009;2.003&#x02013;2.744), CHF (HR&#x02009;=&#x02009;1.916; 95% CI&#x02009;=&#x02009;1.622&#x02013;2.267), diabetes with chronic complications (HR&#x02009;=&#x02009;1.565; 95% CI&#x02009;=&#x02009;1.286&#x02013;1.905), and dementia (HR&#x02009;=&#x02009;1.497; 95% CI&#x02009;=&#x02009;1.118&#x02013;2.005). For GOLD B patients (Figure S4, Panel B in the <xref rid="S1" ref-type="supplementary-material"><bold>Online Supplementary Document</bold></xref>), cancer/metastasis showed HR&#x02009;=&#x02009;2.372 (95% CI&#x02009;=&#x02009;2.116&#x02013;2.659), CHF had HR&#x02009;=&#x02009;1.736 (95% CI&#x02009;=&#x02009;1.553&#x02013;1.940), and peripheral vascular disease (PVD) demonstrated HR&#x02009;=&#x02009;1.467 (95% CI&#x02009;=&#x02009;1.206&#x02013;1.785). The GOLD E cohort (Figure S4, Panel C in the <xref rid="S1" ref-type="supplementary-material"><bold>Online Supplementary Document</bold></xref>) exhibited the following HRs: cancer/metastasis (HR&#x02009;=&#x02009;2.216; 95% CI&#x02009;=&#x02009;1.909&#x02013;2.551), CHF (HR&#x02009;=&#x02009;1.92; 95% CI&#x02009;=&#x02009;1.703&#x02013;2.165), PVD (HR&#x02009;=&#x02009;1.566; 95% CI&#x02009;=&#x02009;1.237&#x02013;1.981), dementia (HR&#x02009;=&#x02009;1.858; 95% CI&#x02009;=&#x02009;1.6&#x02013;2.3), and AMI (HR&#x02009;=&#x02009;1.121; 95% CI&#x02009;=&#x02009;0.811&#x02013;1.55). Common conditions such as DM maintained consistent HRs near 1.0 across all GOLD 2023 classifications. These findings demonstrate that cancer/metastasis and cardiovascular comorbidities, particularly CHF, are significant predictors of mortality in COPD patients across all GOLD 2023 classifications. Additionally, neurological conditions such as dementia show a substantial impact on mortality risk. This consistent pattern of risk across different GOLD classifications suggests that these comorbidities contribute to mortality independently of COPD 2023 classification.</p></sec><sec><title>Association between individual comorbidities and moderate-to-severe exacerbation among COPD</title><p>We examined the relationship between comorbidities and moderate-to-severe exacerbation risk in COPD patients. In the overall analysis, PD showed significant association with exacerbation risk (HR&#x02009;=&#x02009;1.491; 95% CI&#x02009;=&#x02009;1.405&#x02013;1.551), and AMI demonstrated an elevated risk (HR&#x02009;=&#x02009;1.251; 95% CI&#x02009;=&#x02009;1.031&#x02013;1.444) (<xref rid="F3" ref-type="fig"><bold>Figure 3</bold></xref>, Panel E). Stratification by GOLD 2023 classification revealed specific patterns. Among GOLD A patients, PD remained a significant risk factor (HR&#x02009;=&#x02009;1.387; 95% CI&#x02009;=&#x02009;1.212&#x02013;1.587), and CHF exhibited substantial risk (HR&#x02009;=&#x02009;1.292; 95% CI&#x02009;=&#x02009;1.041&#x02013;1.602) (Figure S5, Panel A in the <xref rid="S1" ref-type="supplementary-material"><bold>Online Supplementary Document</bold></xref>). In GOLD B patients, both PD (HR&#x02009;=&#x02009;1.489; 95% CI&#x02009;=&#x02009;1.359&#x02013;1.63) and CHF (HR&#x02009;=&#x02009;1.384; 95% CI&#x02009;=&#x02009;1.214&#x02013;1.585) showed substantial associations with exacerbation (Figure S5, Panel B in the <xref rid="S1" ref-type="supplementary-material"><bold>Online Supplementary Document</bold></xref>). For GOLD E patients, PD demonstrated high risk (HR&#x02009;=&#x02009;1.552; 95% CI&#x02009;=&#x02009;1.411&#x02013;1.708) (Figure S5, Panel C in the <xref rid="S1" ref-type="supplementary-material"><bold>Online Supplementary Document</bold></xref>). According to these findings, comorbidities demonstrated significant associations with moderate-to-severe COPD exacerbations. The analyses identified PD as a crucial risk factor across different GOLD groups, with HRs consistently above 1.3. Additionally, AMI and CHF presented notable risks for exacerbation. The magnitude of these associations varied among GOLD classifications, suggesting that the impact of comorbidities on COPD exacerbations may be influenced by disease severity. These results highlight the importance of comprehensive comorbidity assessment and management in COPD patients to potentially reduce exacerbation risks.</p></sec><sec><title>Sensitivity analysis</title><p>We conducted an additional analysis (Model 2) using different risk factors, including age, gender, BMI, smoking status, COPD family history, CCI, airflow limitation severity, and level of health care facilities, for adjustment as a sensitivity analysis. This alternative risk stratification approach yielded results that are consistent with our main findings. Analysis revealed elevated risk among groups, with group B demonstrating a 1.3-fold increase in five-year all-cause mortality compared to group A (HR&#x02009;=&#x02009;1.338; 95% CI&#x02009;=&#x02009;1.250&#x02013;1.433, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001). Group E exhibited an even greater risk, with a 1.7-fold increase in mortality (HR&#x02009;=&#x02009;1.750; 95% CI&#x02009;=&#x02009;1.626&#x02013;1.884, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001). Similar patterns emerged for moderate-to-severe exacerbations, where group B showed a 1.3-fold higher risk (HR&#x02009;=&#x02009;1.282; 95% CI&#x02009;=&#x02009;1.199&#x02013;1.382, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001) and group E demonstrated approximately 2-fold higher risk (HR&#x02009;=&#x02009;1.921; 95% CI&#x02009;=&#x02009;1.782&#x02013;2.071, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001) compared to group A (Table S1 in the <xref rid="S1" ref-type="supplementary-material"><bold>Online Supplementary Document</bold></xref>).</p></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>This comprehensive analysis of 38&#x02009;928 COPD patients categorised by GOLD 2023 classification demonstrated significant differences in clinical outcomes and mortality risks across groups, with group E consistently showing the poorest prognosis. The five-year mortality rates exhibited a clear gradient, ranging from 8.4% in group A to 22.6% in group E, with HRs of 1.3 and 1.7 times higher in groups B and E compared to group A. Notably, the study suggested that comorbidity patterns were associated with clinical outcomes, where patients with cancer/metastasis and congestive heart failure appeared to have higher mortality risks across GOLD groups. The analysis also highlighted the substantial impact of pulmonary disease on moderate-to-severe exacerbations (HR&#x02009;=&#x02009;1.491), particularly pronounced in group E patients (HR&#x02009;=&#x02009;1.552). These findings underscore the critical importance of both GOLD classification and comorbidity assessment in determining prognosis and managing COPD patients.</p><p>Compared to real-world cohorts from other Asian countries like Korea and China, Taiwanese COPD patients in this study were older with lower CAT scores, but had a similar male proportion, BMI, smoking prevalence, and airway obstruction severity [<xref rid="R16" ref-type="bibr">16</xref>,<xref rid="R42" ref-type="bibr">42</xref>]. In contrast, the German cohort had younger patients, a more balanced gender distribution, higher BMI, and higher CAT scores, while airway obstruction severity and smoking prevalence were similar to the Taiwanese group [<xref rid="R43" ref-type="bibr">43</xref>]. These findings highlight unique characteristics of Taiwanese COPD patients, particularly their older age and lower CAT scores. These variations underscore the importance of accounting for regional differences in COPD management. To date, few studies have compared baseline characteristics across different GOLD 2023 classifications. The GOLD E group in Taiwan showed the highest CAT scores, severe airway obstruction, and the highest all-cause mortality, consistent with similar findings from China [<xref rid="R42" ref-type="bibr">42</xref>].</p><p>The primary purpose of the GOLD classification was initially designed to assist in selecting appropriate pharmacological treatments. However, in practice, it is also used to explore and evaluate the long-term disease course or prognosis of patients [<xref rid="R44" ref-type="bibr">44</xref>,<xref rid="R45" ref-type="bibr">45</xref>]. For example, Gedebjerg et al. analysed a large cohort of 33&#x02009;765 COPD outpatients in Danish hospitals and found that GOLD 2017 was no better than GOLD 2011 in predicting all-cause mortality [<xref rid="R15" ref-type="bibr">15</xref>]. Similarly, Cabrera-Lopez et al. demonstrated in the BODE cohort that the GOLD 2017 classification was less accurate at predicting mortality compared to GOLD 2011 [<xref rid="R46" ref-type="bibr">46</xref>]. Additionally, Brat et al. conducted multicentre research in the Czech Republic, which showed that the GOLD 2023 classification was equally weak compared to previous A&#x02013;D GOLD schemes [<xref rid="R47" ref-type="bibr">47</xref>]. Following this evidence from the aforementioned study, our findings indicated that the prediction of all-cause mortality was comparable between the GOLD 2017 and 2023 criteria. Despite combining groups C and D into group E, our findings found that group E is the highest risk of all-cause mortality and moderate-to-severe exacerbation, followed by group B and group A. These results were consistent with data retrieved from the cohort study Real World Research of Diagnosis and Treatment of COPD in China [<xref rid="R42" ref-type="bibr">42</xref>]. Here are two key aspects related to mortality prediction that merit discussion. First, we found that groups B and C showed similar outcomes, with nearly overlapping curves in the Kaplan-Meier analysis of all-cause mortality, which is similar to the result from the &#x02018;Evaluation of COPD Longitudinally to Identify Surrogate Endpoints (ECLIPSE)&#x02019; cohort [<xref rid="R48" ref-type="bibr">48</xref>]. That indicates that the risk of mortality in group C is more similar to group B rather than group D. Second, the combination of group C and group D into group E, and using group A as the reference group, the mortality risk for group E falls between the original group D and group C. This suggests that merging group C and group D may introduce a potential bias in predicting mortality risk. This could be due to the exclusion of symptom factors affecting disease prognosis when evaluating under group E. This also reasonably explains the inferior predictive ability for mortality in GOLD 2023 compared to GOLD 2017. Aforementioned, patients in the GOLD E group, defined solely by their history of exacerbations, represent a high-risk population. Their frequent exacerbations and severe disease burden contribute to poor outcomes, including increased mortality. These findings emphasize the need for targeted interventions and proactive management for GOLD E patients to reduce exacerbation rates and improve prognosis, as their categorisation may overlook the impact of daily symptoms on overall health.</p><p>Moreover, GOLD 2023 group B patients&#x02019; mortality risk is similar to that of the previous group C, which may be associated with cardiovascular disease. The Danish study specifically noted that group B patients had a three-year cardiovascular mortality rate of 2.9%, significantly higher than group C&#x02019;s 0.5% [<xref rid="R49" ref-type="bibr">49</xref>]. Despite having relatively better lung function, group B patients carried a higher cardiovascular disease burden, used more cardiovascular medications, and exhibited significantly higher cardiovascular mortality rates than group C [<xref rid="R50" ref-type="bibr">50</xref>]. These findings not only emphasise the importance of cardiovascular comorbidity management in COPD patients but also highlight the core value of symptom assessment in COPD clinical practice. Clinicians are advised to closely monitor potential cardiovascular risks in group B patients and implement appropriate treatment strategies.</p><p>A key finding in our study was the confirmed adherence to the proportional hazards assumption across GOLD risk groups. Our validation through log-log survival curve analysis showed parallel patterns, demonstrating that hazard ratios remained constant over time (Figure S3 in the <xref rid="S1" ref-type="supplementary-material"><bold>Online Supplementary Document</bold></xref>). Adjustment for entry time as a covariate produced results consistent with our primary analysis, confirming our statistical approach was appropriate (Table S2 in the <xref rid="S1" ref-type="supplementary-material"><bold>Online Supplementary Document</bold></xref>). Clinically, this finding is significant as it indicates the GOLD risk classification's impact on patient prognosis remains stable over time. This stability enhances the classification's value as a reliable prognostic indicator, allowing clinicians to confidently use it for risk stratification and personalised treatment decisions, ultimately improving management and quality of life for COPD patients.</p><p>COPD extends beyond being a respiratory condition, as it is frequently accompanied by numerous systemic co-morbidities that profoundly affect disease progression, treatment outcomes, and overall quality of life. Therefore, understanding the prevalence of co-morbidities helps to provide holistic patient management. This study demonstrates a significant burden of mild to moderate comorbidities across all COPD groups. Notably, the proportion of patients with severe comorbidities (&#x02265;4) was highest in group E (15.6%) and lowest in group A (12.4%), indicating that patients in group E are more prone to multiple serious comorbidities compared to those in group A. To the best of our knowledge, no directly comparable studies exist that assess comorbidity prevalence in this manner. Nevertheless, prior research has indicated that patients categorised as high-risk (GOLD groups C and D) generally have higher modified CCI scores than those in low-risk groups (GOLD groups A and B), highlighting a greater burden of comorbidities among high-risk individuals [<xref rid="R51" ref-type="bibr">51</xref>]. This variability underscores the importance of considering comorbidity profiles in the management of COPD patients.</p><p>COPD is associated with a high prevalence of various comorbidities, including cardiovascular diseases, hypertension, diabetes, and psychiatric disorders. In our study cohort, the most frequent prevalence of co-morbidities was PD, PUD, DM, CHF, and RED. In the Korean study, the comorbidities were defined by existing literature to evaluate the distribution of comorbidities. The most comorbidities in the Korean cohort were hypertension, asthma, diabetes, dyslipidaemia, and gastro-oesophageal reflux disease [<xref rid="R52" ref-type="bibr">52</xref>]. In German, hypertension, anxiety/depression, diabetes, and congestive heart failure were the most frequent co-morbidities in patients with COPD [<xref rid="R53" ref-type="bibr">53</xref>]. In a systematic review, which included various countries worldwide, it was indicated that comorbidities, particularly cardiovascular diseases and diabetes, are common in COPD patients [<xref rid="R54" ref-type="bibr">54</xref>]. These findings suggest that the prevalence and distribution of comorbidities in COPD patients vary across different regions and populations, influenced by factors such as age, gender, COPD severity, and geographical region [<xref rid="R55" ref-type="bibr">55</xref>,<xref rid="R56" ref-type="bibr">56</xref>]. Moreover, evidence on the prevalence of multi-morbidities in COPD is limited. Our findings reveal that the network of co-occurring chronic diseases is highly complex. In the Taiwanese COPD cohort, the most frequent co-occurrences across all GOLD stages were pulmonary disease with CHF, PUD, and DM. Previous studies have shown that the coexistence of these conditions increases the risk of exacerbations and mortality [<xref rid="R57" ref-type="bibr">57</xref>&#x02013;<xref rid="R59" ref-type="bibr">59</xref>], emphasising the need for tailored public health strategies to effectively manage COPD and its associated comorbidities through a patient-centred rather than a single-disease approach.</p><p>COPD is associated with a higher risk of various cardiovascular diseases, including myocardial infarction, ischemic heart disease, heart failure, and arrhythmias [<xref rid="R60" ref-type="bibr">60</xref>]. The risk of sudden cardiac death is notably higher in COPD patients, especially those with frequent exacerbations [<xref rid="R3" ref-type="bibr">3</xref>]. Moreover, patients with COPD face an increased risk of cardiovascular disease (CVD) and associated mortality. This relationship is influenced by various factors, including acute exacerbations of COPD and the presence of cardiovascular comorbidities [<xref rid="R61" ref-type="bibr">61</xref>,<xref rid="R62" ref-type="bibr">62</xref>]. Similar to previous studies, our findings demonstrated that cardiovascular comorbidities, AMI, CHF, and PVD increased all-cause mortality and moderate-to-severe exacerbation risks across all GOLD categories. Despite the high risk, CVD in COPD patients is often under-recognised and undertreated, highlighting the need for better clinical guidelines and proactive management strategies [<xref rid="R63" ref-type="bibr">63</xref>]. The interplay between COPD and cardiovascular events underscores the importance of integrated care approaches to manage both conditions effectively.</p><p>Our study has significant implications for global COPD management by validating the GOLD 2023 classification system in a large Asian population, providing evidence that this framework effectively stratifies mortality risk and clinical outcomes across different patient groups. The observed clear mortality gradient (from 8.4% in group A to 22.6% in group E) suggests that treatment intensification should be prioritised for patients in groups B and E, particularly those with comorbid cancer/metastasis and congestive heart failure. We recommend implementing routine comprehensive comorbidity screening for all COPD patients and developing personalised management approaches based on specific comorbidity profiles. Patients with cardiovascular comorbidities should receive optimised cardiopulmonary care and closer monitoring, as suggested by the integrated care model in the Spanish study [<xref rid="R64" ref-type="bibr">64</xref>]; while patients with malignancies require integrated oncology-pulmonology care pathways. Future studies should focus on validating these findings in diverse global populations, particularly in resource-limited settings where comorbidity patterns may differ. Prospective multicentre trials investigating targeted interventions based on GOLD classification and comorbidity profiles are needed, alongside studies examining the impact of comorbidity-specific interventions on exacerbation rates and mortality. We utilised a large registry-based Asian cohort to comprehensively evaluate the GOLD 2023 classification system, providing valuable complementary perspectives for research in COPD, comorbidities, and their prognosis. This work contributes to enhancing our understanding of COPD disease characteristics across different populations and provides clinicians with stronger evidence to improve patient care and prognostic assessment, ultimately advancing the optimisation and development of global COPD management strategies.</p><p>We identified several key risk factors for mortality and exacerbation in COPD patients, including advanced age, smoking history, lower BMI, severe airflow obstruction, presence of wheezing, and higher CCI, supporting previous findings [<xref rid="R65" ref-type="bibr">65</xref>&#x02013;<xref rid="R68" ref-type="bibr">68</xref>]. Notably, wheezing emerged as an independent risk factor not only for moderate-to-severe exacerbations but also for all-cause mortality, highlighting its critical role as an important clinical phenotype in COPD as a previous study reported [<xref rid="R65" ref-type="bibr">65</xref>]. Given the association between wheezing and frequent exacerbations, and greater impairment in lung function, wheezing may serve as a valuable and intuitive marker for assessing symptom severity in COPD in clinical practice. However, evidence regarding the association between wheezing and all-cause mortality in COPD is limited. In a previous study, the participants with ACO exhibited a significant increase in all-cause mortality compared to those without [<xref rid="R66" ref-type="bibr">66</xref>]. One of the possible explanations of our finding is that patients with wheezing in group E have a higher proportion of patients with coexistence of asthma, which contributes to the higher risk of all-cause death.</p><p>At baseline, it was observed that 28.3% of group A patients were using ICS-containing inhalers, a finding worth discussing, as this data reflects medication usage measured during the first baseline assessment when patients initially entered Taiwan's COPD P4P program. This relatively high percentage directly demonstrates the gap between routine clinical practice and clinical guidelines (which discourage ICS use in less symptomatic patients). Factors contributing to this discrepancy may include: physicians' reluctance to discontinue established treatment regimens even after patient symptom improvement, and patients' resistance to medication adjustments due to psychological reassurance or perceived efficacy [<xref rid="R69" ref-type="bibr">69</xref>,<xref rid="R70" ref-type="bibr">70</xref>]. Taiwan's COPD P4P program addresses this issue through its standardised care model, which requires all participants to undergo a comprehensive reassessment of disease status after entering the program, followed by appropriate medication adjustments. This systematic intervention helps identify and correct previously inappropriate medication use, including unnecessary ICS use among group A patients. Such programs are crucial for narrowing the gap between guidelines and practice, not only improving treatment appropriateness but also reducing unnecessary resource consumption and minimising potential side effects.</p><p>There are some limitations to this study. First, our study cohort is not population-based, which may limit the generalizability of results. Significant differences exist between the P4P and non-P4P groups had been reported, including slightly older, having lower CCI scores, lower single-inhaler but higher dual-inhaler usage rates, and better medication adherence [<xref rid="R71" ref-type="bibr">71</xref>], suggesting that P4P program patients may have better treatment compliance due to more regular follow-ups or improved health care access. Despite this selection bias, our patients were recruited from multiple health care facilities of varying levels, and stratified analysis by health care facility level showed consistent results, demonstrating the robustness of our conclusions (Table S3 in the <xref rid="S1" ref-type="supplementary-material"><bold>Online Supplementary Document</bold></xref>). Second, despite accounting for various potential confounders in this real-world study, we acknowledge limitations including residual confounding factors (environmental exposures, physical activity, and nutrition) and the absence of important COPD prognostic factors such as genetic backgrounds in our database. Additionally, as our study focused on a Taiwanese cohort, results may have limited generalisability to other populations with different health care systems or genetic profiles. Future research should incorporate these variables and extend findings across diverse populations and health care contexts. Third, some degree of recall bias may exist in our collection of self-reported smoking history and lifestyle factors. To minimise this potential bias, all health care professionals involved in data collection underwent professional training to ensure standardised interview processes. We implemented validated structured questionnaires for follow-up care, reducing inconsistencies in question formulation. During statistical analysis, we adjusted for relevant confounding factors to mitigate this bias. For future research, we recommend incorporating objective measurement methods, such as biomarker detection (for example, fractional exhaled nitric oxide, which serves as a useful indicator for determining smoking intensity), to enhance data reliability. Fourth, underreporting or misclassification of comorbidities was possible. To minimise this bias, we defined comorbidities as present if the relevant code appeared at least once in admission records or three times in outpatient department diagnosis codes. The validity of this method has been proven [<xref rid="R72" ref-type="bibr">72</xref>]. Moreover, we applied the well-validated ICD coding algorithm based on the CDMF CCI scheme described by Glasheen et al. This approach provides consistency in condition identification and has demonstrated reliability across multiple populations. By adopting this validated coding system, we were able to mitigate the potential impact of data quality issues on our research results [<xref rid="R39" ref-type="bibr">39</xref>]. Fifth, the potential limitation of using ICD-10 codes and claims-based definitions for identifying outcomes, as this approach may introduce some degree of outcome misclassification. Although our definitions for outcomes are consistent with methodologies employed in previous research, we recognize that claims data cannot perfectly capture all clinical nuances. Nevertheless, we believe that any potential misclassification would occur randomly across our three groups, thereby preserving the validity of our between-group comparisons and the overall reliability of our findings. Sixth, this study is the lack of cause-of-death information in our database, which prevented us from distinguishing between respiratory-related deaths and deaths from other causes. This may have resulted in non-respiratory deaths obscuring the accurate assessment of COPD-specific mortality. Therefore, our all-cause mortality analysis results should be interpreted with caution. Future studies with access to cause-specific mortality data would help more precisely elucidate the associations between predictors and COPD-specific outcomes.</p></sec><sec sec-type="conclusions"><title>CONCLUSIONS</title><p>In conclusion, in this study, we reinforced the clinical value of the GOLD 2023 classification system for risk stratification in COPD patients. The notable association between specific comorbidities and adverse outcomes underscores the critical need for comprehensive patient assessment beyond conventional COPD parameters. The consistent impact of cardiovascular and pulmonary comorbidities across all GOLD groups suggests that systematic comorbidity screening and management should be integrated into routine COPD care protocols. These findings provide clinicians with valuable insights for developing more targeted therapeutic approaches and emphasize the importance of personalized treatment strategies that consider both COPD severity and comorbidity burden to optimize patient outcomes.</p></sec><sec sec-type="supplementary-material"><title>Additional material</title><supplementary-material id="S1" position="float" content-type="local-data"><caption><title>
<ext-link xlink:href="https://jogh.org/documents/2025/jogh-15-04152-s001.pdf" ext-link-type="uri">Online Supplementary Document</ext-link>
</title></caption><media xlink:href="jogh-15-04152-s001.pdf" id="d67e2056" position="anchor"/></supplementary-material></sec></body><back><ack><title>Acknowledgements</title><p>The authors would like to thank the Applied Health Research Data Integration Service of the National Health Insurance Administration for their help in providing clinical data.</p><p><bold>Ethics statement:</bold> The Institutional Review Board of CCH waived off the requirement for informed consent and approved the study (approval number 230512). All patient records and data were deidentified and anonymized prior to analysis.</p><p><bold>Data availability:</bold> Clinical research data from Applied Health Research Data Integration Service from National Health Insurance Administration supported the findings of this study. Restrictions apply to the availability of these data and they are therefore not publicly available.</p></ack><fn-group><fn fn-type="financial-disclosure"><p><bold>Funding:</bold> This research was funded by Changhua Christian Hospital, grant number 112-CCH-IRP-056.</p></fn><fn fn-type="other"><p><bold>Authorship contributions:</bold> CHL and CJY contributed to conceptualising the project and investigation. CHL and YRL contributed to the writing of the original draft. YRL contributed to data collection, curation, and formal analysis. SLC, HCW, HIL, and IWC contributed to methodology, writing, reviewing, and editing. PCC and HWC contributed to validation and interpretation of data.</p></fn><fn fn-type="COI-statement"><p><bold>Disclosure of interest:</bold> The authors completed the ICMJE Disclosure of Interest Form (available upon request from the corresponding author) and disclose no relevant interests.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="R1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Safiri</surname><given-names>S</given-names></name><name><surname>Carson-Chahhoud</surname><given-names>K</given-names></name><name><surname>Noori</surname><given-names>M</given-names></name><name><surname>Nejadghaderi</surname><given-names>SA</given-names></name><name><surname>Sullman</surname><given-names>MJM</given-names></name><name><surname>Heris</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Burden of chronic obstructive pulmonary disease and its attributable risk factors in 204 countries and territories, 1990- 2019: results from the global burden of disease study 2019.</article-title>
<source>BMJ</source>. <year>2022</year>;<volume>378</volume>:<elocation-id>e069679</elocation-id>. <pub-id pub-id-type="doi">10.1136/bmj-2021-069679</pub-id><pub-id pub-id-type="pmid">35896191</pub-id>
</mixed-citation></ref><ref id="R2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Kuhn</surname><given-names>M</given-names></name><name><surname>Prettner</surname><given-names>K</given-names></name><name><surname>Yu</surname><given-names>F</given-names></name><name><surname>Yang</surname><given-names>T</given-names></name><name><surname>B&#x000e4;rnighausen</surname><given-names>T</given-names></name><etal/></person-group><article-title>The global economic burden of chronic obstructive pulmonary disease for 204 countries and territories in 2020-50: a health-augmented macroeconomic modelling study.</article-title>
<source>Lancet Glob Health</source>. <year>2023</year>;<volume>11</volume>:<fpage>e1183</fpage>&#x02013;<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1016/S2214-109X(23)00217-6</pub-id><pub-id pub-id-type="pmid">37474226</pub-id>
</mixed-citation></ref><ref id="R3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boers</surname><given-names>E</given-names></name><name><surname>Barrett</surname><given-names>M</given-names></name><name><surname>Su</surname><given-names>JG</given-names></name><name><surname>Benjafield</surname><given-names>AV</given-names></name><name><surname>Sinha</surname><given-names>S</given-names></name><name><surname>Kaye</surname><given-names>L</given-names></name><etal/></person-group><article-title>Global Burden of Chronic Obstructive Pulmonary Disease Through 2050.</article-title>
<source>JAMA Netw Open</source>. <year>2023</year>;<volume>6</volume>:<elocation-id>e2346598</elocation-id>. <pub-id pub-id-type="doi">10.1001/jamanetworkopen.2023.46598</pub-id><pub-id pub-id-type="pmid">38060225</pub-id>
</mixed-citation></ref><ref id="R4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Celli</surname><given-names>B</given-names></name><name><surname>Fabbri</surname><given-names>L</given-names></name><name><surname>Criner</surname><given-names>G</given-names></name><name><surname>Martinez</surname><given-names>FJ</given-names></name><name><surname>Mannino</surname><given-names>D</given-names></name><name><surname>Vogelmeier</surname><given-names>C</given-names></name><etal/></person-group><article-title>Definition and nomenclature of chronic obstructive pulmonary disease: time for its revision.</article-title>
<source>Am J Respir Crit Care Med</source>. <year>2022</year>;<volume>206</volume>:<fpage>1317</fpage>&#x02013;<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1164/rccm.202204-0671PP</pub-id><pub-id pub-id-type="pmid">35914087</pub-id>
</mixed-citation></ref><ref id="R5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venkatesan</surname><given-names>P</given-names></name></person-group><article-title>GOLD COPD report: 2023 update.</article-title>
<source>Lancet Respir Med</source>. <year>2023</year>;<volume>11</volume>:<fpage>18</fpage>. <pub-id pub-id-type="doi">10.1016/S2213-2600(22)00494-5</pub-id><pub-id pub-id-type="pmid">36462509</pub-id>
</mixed-citation></ref><ref id="R6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skajaa</surname><given-names>N</given-names></name><name><surname>Laugesen</surname><given-names>K</given-names></name><name><surname>Horv&#x000e1;th-Puh&#x000f3;</surname><given-names>E</given-names></name><name><surname>S&#x000f8;rensen</surname><given-names>HT</given-names></name></person-group><article-title>Comorbidities and mortality among patients with chronic obstructive pulmonary disease.</article-title>
<source>BMJ Open Respir Res</source>. <year>2023</year>;<volume>10</volume>:<elocation-id>e001798</elocation-id>. <pub-id pub-id-type="doi">10.1136/bmjresp-2023-001798</pub-id><pub-id pub-id-type="pmid">37797964</pub-id>
</mixed-citation></ref><ref id="R7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fabbri</surname><given-names>LM</given-names></name><name><surname>Celli</surname><given-names>BR</given-names></name><name><surname>Agust&#x000ed;</surname><given-names>A</given-names></name><name><surname>Criner</surname><given-names>GJ</given-names></name><name><surname>Dransfield</surname><given-names>MT</given-names></name><name><surname>Divo</surname><given-names>M</given-names></name><etal/></person-group><article-title>COPD and multimorbidity: recognising and addressing a syndemic occurrence.</article-title>
<source>Lancet Respir Med</source>. <year>2023</year>;<volume>11</volume>:<fpage>1020</fpage>&#x02013;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1016/S2213-2600(23)00261-8</pub-id><pub-id pub-id-type="pmid">37696283</pub-id>
</mixed-citation></ref><ref id="R8"><label>8</label><mixed-citation publication-type="book">Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Initiative for Chronic Lung Disease (2023 Report). Fontana, Wisconsin, USA: Global Initiative for Chronic Lung Disease; 2023. Available: <ext-link xlink:href="https://goldcopd.org/2023-gold-report-2/" ext-link-type="uri">https://goldcopd.org/2023-gold-report-2/</ext-link>. Accessed: 30 December 2024.</mixed-citation></ref><ref id="R9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tudoric</surname><given-names>N</given-names></name><name><surname>Koblizek</surname><given-names>V</given-names></name><name><surname>Miravitlles</surname><given-names>M</given-names></name><name><surname>Valipour</surname><given-names>A</given-names></name><name><surname>Milenkovic</surname><given-names>B</given-names></name><name><surname>Barczyk</surname><given-names>A</given-names></name><etal/></person-group><article-title>GOLD 2017 on the way to a phenotypic approach? Analysis from the Phenotypes of COPD in Central and Eastern Europe (POPE) Cohort.</article-title>
<source>Eur Respir J</source>. <year>2017</year>;<volume>49</volume>:<elocation-id>1602518</elocation-id>. <pub-id pub-id-type="doi">10.1183/13993003.02518-2016</pub-id><pub-id pub-id-type="pmid">28446560</pub-id>
</mixed-citation></ref><ref id="R10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haughney</surname><given-names>J</given-names></name><name><surname>Gruffydd-Jones</surname><given-names>K</given-names></name><name><surname>Roberts</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>AJ</given-names></name><name><surname>Hardwell</surname><given-names>A</given-names></name><name><surname>McGarvey</surname><given-names>L</given-names></name></person-group><article-title>The distribution of COPD in UK general practice using the new GOLD classification.</article-title>
<source>Eur Respir J</source>. <year>2014</year>;<volume>43</volume>:<fpage>993</fpage>&#x02013;<lpage>1002</lpage>. <pub-id pub-id-type="doi">10.1183/09031936.00065013</pub-id><pub-id pub-id-type="pmid">24176990</pub-id>
</mixed-citation></ref><ref id="R11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>&#x000c7;olak</surname><given-names>Y</given-names></name><name><surname>Afzal</surname><given-names>S</given-names></name><name><surname>Marott</surname><given-names>JL</given-names></name><name><surname>Nordestgaard</surname><given-names>BG</given-names></name><name><surname>Vestbo</surname><given-names>J</given-names></name><name><surname>Ingebrigtsen</surname><given-names>TS</given-names></name></person-group><article-title>Prognosis of COPD depends on severity of exacerbation history: A population-based analysis.</article-title>
<source>Respir Med</source>. <year>2019</year>;<volume>155</volume>:<fpage>141</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.rmed.2019.07.021</pub-id><pub-id pub-id-type="pmid">31362177</pub-id>
</mixed-citation></ref><ref id="R12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vogelmeier</surname><given-names>CF</given-names></name><name><surname>Friedrich</surname><given-names>FW</given-names></name><name><surname>Timpel</surname><given-names>P</given-names></name><name><surname>Kossack</surname><given-names>N</given-names></name><name><surname>Diesing</surname><given-names>J</given-names></name><name><surname>Pignot</surname><given-names>M</given-names></name><etal/></person-group><article-title>Impact of COPD on mortality: An 8-year observational retrospective healthcare claims database cohort study.</article-title>
<source>Respir Med</source>. <year>2024</year>;<volume>222</volume>:<elocation-id>107506</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.rmed.2023.107506</pub-id><pub-id pub-id-type="pmid">38151176</pub-id>
</mixed-citation></ref><ref id="R13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miravitlles</surname><given-names>M</given-names></name><name><surname>Kostikas</surname><given-names>K</given-names></name><name><surname>Bizymi</surname><given-names>N</given-names></name><name><surname>Tzanakis</surname><given-names>N</given-names></name></person-group><article-title>A Novel Figure and Algorithm for the Gold ABE Classification.</article-title>
<source>Arch Bronconeumol</source>. <year>2023</year>;<volume>59</volume>:<fpage>702</fpage>&#x02013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1016/j.arbres.2023.06.001</pub-id><pub-id pub-id-type="pmid">37355409</pub-id>
</mixed-citation></ref><ref id="R14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Criner</surname><given-names>RN</given-names></name><name><surname>Labaki</surname><given-names>WW</given-names></name><name><surname>Regan</surname><given-names>EA</given-names></name><name><surname>Bon</surname><given-names>JM</given-names></name><name><surname>Soler</surname><given-names>X</given-names></name><name><surname>Bhatt</surname><given-names>SP</given-names></name><etal/></person-group><article-title>Mortality and Exacerbations by Global Initiative for Chronic Obstructive Lung Disease Groups ABCD: 2011 Versus 2017 in the COPDGene&#x000ae; Cohort.</article-title>
<source>Chronic Obstr Pulm Dis (Miami)</source>. <year>2019</year>;<volume>6</volume>:<fpage>64</fpage>&#x02013;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.15326/jcopdf.6.1.2018.0130</pub-id><pub-id pub-id-type="pmid">30775425</pub-id>
</mixed-citation></ref><ref id="R15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gedebjerg</surname><given-names>A</given-names></name><name><surname>Sz&#x000e9;pligeti</surname><given-names>SK</given-names></name><name><surname>Wackerhausen</surname><given-names>LH</given-names></name><name><surname>Horv&#x000e1;th-Puh&#x000f3;</surname><given-names>E</given-names></name><name><surname>Dahl</surname><given-names>R</given-names></name><name><surname>Hansen</surname><given-names>JG</given-names></name><etal/></person-group><article-title>Prediction of mortality in patients with chronic obstructive pulmonary disease with the new Global Initiative for Chronic Obstructive Lung Disease 2017 classification: a cohort study.</article-title>
<source>Lancet Respir Med</source>. <year>2018</year>;<volume>6</volume>:<fpage>204</fpage>&#x02013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1016/S2213-2600(18)30002-X</pub-id><pub-id pub-id-type="pmid">29331311</pub-id>
</mixed-citation></ref><ref id="R16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>JH</given-names></name><name><surname>Lee</surname><given-names>CH</given-names></name><name><surname>Um</surname><given-names>SJ</given-names></name><name><surname>Park</surname><given-names>YB</given-names></name><name><surname>Yoo</surname><given-names>KH</given-names></name><name><surname>Jung</surname><given-names>KS</given-names></name><etal/></person-group><article-title>Clinical impacts of the classification by 2017 GOLD guideline comparing previous ones on outcomes of COPD in real-world cohorts.</article-title>
<source>Int J Chron Obstruct Pulmon Dis</source>. <year>2018</year>;<volume>13</volume>:<fpage>3473</fpage>&#x02013;<lpage>84</lpage>. <pub-id pub-id-type="doi">10.2147/COPD.S177238</pub-id><pub-id pub-id-type="pmid">30498337</pub-id>
</mixed-citation></ref><ref id="R17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>W</given-names></name><name><surname>Zhou</surname><given-names>A</given-names></name><name><surname>Zeng</surname><given-names>Y</given-names></name><name><surname>Lin</surname><given-names>L</given-names></name><name><surname>Song</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><etal/></person-group><article-title>Prediction of Hospitalization and Mortality in Patients with Chronic Obstructive Pulmonary Disease with the New Global Initiative for Chronic Obstructive Lung Disease 2023 Group Classification: A Prospective Cohort and a Retrospective Analysis.</article-title>
<source>Int J Chron Obstruct Pulmon Dis</source>. <year>2023</year>;<volume>18</volume>:<fpage>2341</fpage>&#x02013;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.2147/COPD.S429104</pub-id><pub-id pub-id-type="pmid">37908629</pub-id>
</mixed-citation></ref><ref id="R18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Westerik</surname><given-names>JA</given-names></name><name><surname>Metting</surname><given-names>EI</given-names></name><name><surname>van Boven</surname><given-names>JF</given-names></name><name><surname>Tiersma</surname><given-names>W</given-names></name><name><surname>Kocks</surname><given-names>JW</given-names></name><name><surname>Schermer</surname><given-names>TR</given-names></name></person-group><article-title>Associations between chronic comorbidity and exacerbation risk in primary care patients with COPD.</article-title>
<source>Respir Res</source>. <year>2017</year>;<volume>18</volume>:<fpage>31</fpage>. <pub-id pub-id-type="doi">10.1186/s12931-017-0512-2</pub-id><pub-id pub-id-type="pmid">28166777</pub-id>
</mixed-citation></ref><ref id="R19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Almagro</surname><given-names>P</given-names></name><name><surname>Cabrera</surname><given-names>FJ</given-names></name><name><surname>Diez</surname><given-names>J</given-names></name><name><surname>Boixeda</surname><given-names>R</given-names></name><name><surname>Alonso Ortiz</surname><given-names>MB</given-names></name><name><surname>Murio</surname><given-names>C</given-names></name><etal/></person-group><article-title>Comorbidities and short-term prognosis in patients hospitalized for acute exacerbation of COPD: the EPOC en Servicios de medicina interna (ESMI) study.</article-title>
<source>Chest</source>. <year>2012</year>;<volume>142</volume>:<fpage>1126</fpage>&#x02013;<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1378/chest.11-2413</pub-id><pub-id pub-id-type="pmid">23303399</pub-id>
</mixed-citation></ref><ref id="R20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Argano</surname><given-names>C</given-names></name><name><surname>Scichilone</surname><given-names>N</given-names></name><name><surname>Natoli</surname><given-names>G</given-names></name><name><surname>Nobili</surname><given-names>A</given-names></name><name><surname>Corazza</surname><given-names>GR</given-names></name><name><surname>Mannucci</surname><given-names>PM</given-names></name><etal/></person-group><article-title>Pattern of comorbidities and 1-year mortality in elderly patients with COPD hospitalized in internal medicine wards: data from the RePoSI Registry.</article-title>
<source>Intern Emerg Med</source>. <year>2021</year>;<volume>16</volume>:<fpage>389</fpage>&#x02013;<lpage>400</lpage>. <pub-id pub-id-type="doi">10.1007/s11739-020-02412-1</pub-id><pub-id pub-id-type="pmid">32720248</pub-id>
</mixed-citation></ref><ref id="R21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Torres</surname><given-names>JP</given-names></name><name><surname>Casanova</surname><given-names>C</given-names></name><name><surname>Mar&#x000ed;n</surname><given-names>JM</given-names></name><name><surname>Pinto-Plata</surname><given-names>V</given-names></name><name><surname>Divo</surname><given-names>M</given-names></name><name><surname>Zulueta</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>Prognostic evaluation of COPD patients: GOLD 2011 versus BODE and the COPD comorbidity index COTE.</article-title>
<source>Thorax</source>. <year>2014</year>;<volume>69</volume>:<fpage>799</fpage>&#x02013;<lpage>804</lpage>. <pub-id pub-id-type="doi">10.1136/thoraxjnl-2014-205770</pub-id><pub-id pub-id-type="pmid">24969641</pub-id>
</mixed-citation></ref><ref id="R22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>CL</given-names></name><name><surname>Lin</surname><given-names>MH</given-names></name><name><surname>Chen</surname><given-names>PS</given-names></name><name><surname>Tsai</surname><given-names>YC</given-names></name><name><surname>Shen</surname><given-names>LS</given-names></name><name><surname>Kuo</surname><given-names>HC</given-names></name><etal/></person-group><article-title>Using the BODE Index and Comorbidities to Predict Health Utilization Resources in Chronic Obstructive Pulmonary Disease.</article-title>
<source>Int J Chron Obstruct Pulmon Dis</source>. <year>2020</year>;<volume>15</volume>:<fpage>389</fpage>&#x02013;<lpage>95</lpage>. <pub-id pub-id-type="doi">10.2147/COPD.S234363</pub-id><pub-id pub-id-type="pmid">32110007</pub-id>
</mixed-citation></ref><ref id="R23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santos</surname><given-names>NCD</given-names></name><name><surname>Miravitlles</surname><given-names>M</given-names></name><name><surname>Camelier</surname><given-names>AA</given-names></name><name><surname>Almeida</surname><given-names>VDC</given-names></name><name><surname>Maciel</surname><given-names>RRBT</given-names></name><name><surname>Camelier</surname><given-names>FWR</given-names></name></person-group><article-title>Prevalence and Impact of Comorbidities in Individuals with Chronic Obstructive Pulmonary Disease: A Systematic Review.</article-title>
<source>Tuberc Respir Dis (Seoul)</source>. <year>2022</year>;<volume>85</volume>:<fpage>205</fpage>&#x02013;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.4046/trd.2021.0179</pub-id><pub-id pub-id-type="pmid">35618259</pub-id>
</mixed-citation></ref><ref id="R24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>YY</given-names></name><name><surname>Huang</surname><given-names>CS</given-names></name></person-group><article-title>Aging in Taiwan: Building a Society for Active Aging and Aging in Place.</article-title>
<source>Gerontologist</source>. <year>2016</year>;<volume>56</volume>:<fpage>176</fpage>&#x02013;<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1093/geront/gnv107</pub-id><pub-id pub-id-type="pmid">26589450</pub-id>
</mixed-citation></ref><ref id="R25"><label>25</label><mixed-citation publication-type="book">Antoniou ASG, Burke RJ, Cooper CL. The aging workforce handbook: individual, organizational and societal challenges. 1st ed. Bingley, UK: Emerald Publishing Limited; 2016.</mixed-citation></ref><ref id="R26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wing</surname><given-names>K</given-names></name><name><surname>Williamson</surname><given-names>E</given-names></name><name><surname>Carpenter</surname><given-names>JR</given-names></name><name><surname>Wise</surname><given-names>L</given-names></name><name><surname>Schneeweiss</surname><given-names>S</given-names></name><name><surname>Smeeth</surname><given-names>L</given-names></name><etal/></person-group><article-title>Real-world effects of medications for chronic obstructive pulmonary disease: protocol for a UK population-based non-interventional cohort study with validation against randomised trial results.</article-title>
<source>BMJ Open</source>. <year>2018</year>;<volume>8</volume>:<elocation-id>e019475</elocation-id>. <pub-id pub-id-type="doi">10.1136/bmjopen-2017-019475</pub-id><pub-id pub-id-type="pmid">29581202</pub-id>
</mixed-citation></ref><ref id="R27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wing</surname><given-names>K</given-names></name><name><surname>Williamson</surname><given-names>E</given-names></name><name><surname>Carpenter</surname><given-names>JR</given-names></name><name><surname>Wise</surname><given-names>L</given-names></name><name><surname>Schneeweiss</surname><given-names>S</given-names></name><name><surname>Smeeth</surname><given-names>L</given-names></name><etal/></person-group><article-title>Real world effects of COPD medications: a cohort study with validation against results from randomised controlled trials.</article-title>
<source>Eur Respir J</source>. <year>2021</year>;<volume>57</volume>:<elocation-id>2001586</elocation-id>. <pub-id pub-id-type="doi">10.1183/13993003.01586-2020</pub-id><pub-id pub-id-type="pmid">33093119</pub-id>
</mixed-citation></ref><ref id="R28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burns</surname><given-names>L</given-names></name><name><surname>Roux</surname><given-names>NL</given-names></name><name><surname>Kalesnik-Orszulak</surname><given-names>R</given-names></name><name><surname>Christian</surname><given-names>J</given-names></name><name><surname>Hukkelhoven</surname><given-names>M</given-names></name><name><surname>Rockhold</surname><given-names>F</given-names></name><etal/></person-group><article-title>Real-World Evidence for Regulatory Decision-Making: Guidance From Around the World.</article-title>
<source>Clin Ther</source>. <year>2022</year>;<volume>44</volume>:<fpage>420</fpage>&#x02013;<lpage>37</lpage>. <pub-id pub-id-type="doi">10.1016/j.clinthera.2022.01.012</pub-id><pub-id pub-id-type="pmid">35181179</pub-id>
</mixed-citation></ref><ref id="R29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trotter</surname><given-names>JP</given-names></name></person-group><article-title>Patient registries: a new gold standard for &#x0201c;real world&#x0201d; research.</article-title>
<source>Ochsner J</source>. <year>2002</year>;<volume>4</volume>:<fpage>211</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="pmid">22826660</pub-id>
</mixed-citation></ref><ref id="R30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sedrakyan</surname><given-names>A</given-names></name><name><surname>Marinac-Dabic</surname><given-names>D</given-names></name><name><surname>Campbell</surname><given-names>B</given-names></name><name><surname>Aryal</surname><given-names>S</given-names></name><name><surname>Baird</surname><given-names>CE</given-names></name><name><surname>Goodney</surname><given-names>P</given-names></name><etal/></person-group><article-title>Advancing the Real-World Evidence for Medical Devices through Coordinated Registry Networks.</article-title>
<source>BMJ Surg Interv Health Technol</source>. <year>2022</year>;<volume>4</volume>:<elocation-id>e000123</elocation-id>. <pub-id pub-id-type="doi">10.1136/bmjsit-2021-000123</pub-id><pub-id pub-id-type="pmid">36393894</pub-id>
</mixed-citation></ref><ref id="R31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gliklich</surname><given-names>RE</given-names></name><name><surname>Leavy</surname><given-names>MB</given-names></name></person-group><article-title>Assessing Real-World Data Quality: The Application of Patient Registry Quality Criteria to Real-World Data and Real-World Evidence.</article-title>
<source>Ther Innov Regul Sci</source>. <year>2020</year>;<volume>54</volume>:<fpage>303</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1007/s43441-019-00058-6</pub-id><pub-id pub-id-type="pmid">32072577</pub-id>
</mixed-citation></ref><ref id="R32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ip</surname><given-names>MS</given-names></name><name><surname>Ko</surname><given-names>FW</given-names></name><name><surname>Lau</surname><given-names>AC</given-names></name><name><surname>Yu</surname><given-names>WC</given-names></name><name><surname>Tang</surname><given-names>KS</given-names></name><name><surname>Choo</surname><given-names>K</given-names></name><etal/></person-group><article-title>Updated spirometric reference values for adult Chinese in Hong Kong and implications on clinical utilization.</article-title>
<source>Chest</source>. <year>2006</year>;<volume>129</volume>:<fpage>384</fpage>&#x02013;<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1378/chest.129.2.384</pub-id><pub-id pub-id-type="pmid">16478856</pub-id>
</mixed-citation></ref><ref id="R33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eltayara</surname><given-names>L</given-names></name><name><surname>Becklake</surname><given-names>MR</given-names></name><name><surname>Volta</surname><given-names>CA</given-names></name><name><surname>Milic-Emili</surname><given-names>J</given-names></name></person-group><article-title>Relationship between chronic dyspnea and expiratory flow limitation in patients with chronic obstructive pulmonary disease.</article-title>
<source>Am J Respir Crit Care Med</source>. <year>1996</year>;<volume>154</volume>:<fpage>1726</fpage>&#x02013;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1164/ajrccm.154.6.8970362</pub-id><pub-id pub-id-type="pmid">8970362</pub-id>
</mixed-citation></ref><ref id="R34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>PW</given-names></name><name><surname>Harding</surname><given-names>G</given-names></name><name><surname>Berry</surname><given-names>P</given-names></name><name><surname>Wiklund</surname><given-names>I</given-names></name><name><surname>Chen</surname><given-names>WH</given-names></name><name><surname>Kline Leidy</surname><given-names>N</given-names></name></person-group><article-title>Development and first validation of the COPD Assessment Test.</article-title>
<source>Eur Respir J</source>. <year>2009</year>;<volume>34</volume>:<fpage>648</fpage>&#x02013;<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1183/09031936.00102509</pub-id><pub-id pub-id-type="pmid">19720809</pub-id>
</mixed-citation></ref><ref id="R35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>PJ</given-names></name><name><surname>Yang</surname><given-names>KY</given-names></name><name><surname>Perng</surname><given-names>WC</given-names></name><name><surname>Lin</surname><given-names>KC</given-names></name><name><surname>Wang</surname><given-names>KY</given-names></name></person-group><article-title>Effect of dyspnea on frailty stages and related factors in Taiwanese men with COPD.</article-title>
<source>Int J Chron Obstruct Pulmon Dis</source>. <year>2018</year>;<volume>13</volume>:<fpage>2463</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.2147/COPD.S172694</pub-id><pub-id pub-id-type="pmid">30147312</pub-id>
</mixed-citation></ref><ref id="R36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiklund</surname><given-names>I</given-names></name><name><surname>Berry</surname><given-names>P</given-names></name><name><surname>Lu</surname><given-names>KX</given-names></name><name><surname>Fang</surname><given-names>J</given-names></name><name><surname>Fu</surname><given-names>C</given-names></name></person-group><article-title>The Chinese translation of COPD Assessment TestTM (CAT) provides a valid and reliable measurement of COPD health status in Chinese COPD patients.</article-title>
<source>Am J Respir Crit Care Med</source>. <year>2010</year>;<volume>181</volume>:<fpage>3575</fpage>.</mixed-citation></ref><ref id="R37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>SL</given-names></name><name><surname>Lin</surname><given-names>CH</given-names></name><name><surname>Wang</surname><given-names>CC</given-names></name><name><surname>Chan</surname><given-names>MC</given-names></name><name><surname>Hsu</surname><given-names>JY</given-names></name><name><surname>Hang</surname><given-names>LW</given-names></name><etal/></person-group><article-title>Comparison between COPD Assessment Test (CAT) and modified Medical Research Council (mMRC) dyspnea scores for evaluation of clinical symptoms, comorbidities and medical resources utilization in COPD patients.</article-title>
<source>J Formos Med Assoc</source>. <year>2019</year>;<volume>118</volume>:<fpage>429</fpage>&#x02013;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1016/j.jfma.2018.06.018</pub-id><pub-id pub-id-type="pmid">30150099</pub-id>
</mixed-citation></ref><ref id="R38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>WY</given-names></name><name><surname>Hsiao</surname><given-names>CH</given-names></name><name><surname>Chen</surname><given-names>YC</given-names></name><name><surname>Ho</surname><given-names>CH</given-names></name><name><surname>Wang</surname><given-names>JJ</given-names></name><name><surname>Hsing</surname><given-names>CH</given-names></name><etal/></person-group><article-title>Cisplatin Nephrotoxicity Might Have a Sex Difference. An analysis Based on Women&#x02019;s Sex Hormone Changes.</article-title>
<source>J Cancer</source>. <year>2017</year>;<volume>8</volume>:<fpage>3939</fpage>&#x02013;<lpage>44</lpage>. <pub-id pub-id-type="doi">10.7150/jca.20083</pub-id><pub-id pub-id-type="pmid">29187868</pub-id>
</mixed-citation></ref><ref id="R39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glasheen</surname><given-names>WP</given-names></name><name><surname>Cordier</surname><given-names>T</given-names></name><name><surname>Gumpina</surname><given-names>R</given-names></name><name><surname>Haugh</surname><given-names>G</given-names></name><name><surname>Davis</surname><given-names>J</given-names></name><name><surname>Renda</surname><given-names>A</given-names></name></person-group><article-title>Charlson Comorbidity Index: ICD-9 Update and ICD-10 Translation.</article-title>
<source>Am Health Drug Benefits</source>. <year>2019</year>;<volume>12</volume>:<fpage>188</fpage>&#x02013;<lpage>97</lpage>.<pub-id pub-id-type="pmid">31428236</pub-id>
</mixed-citation></ref><ref id="R40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wallstr&#x000f6;m</surname><given-names>O</given-names></name><name><surname>Stridsman</surname><given-names>C</given-names></name><name><surname>Lindberg</surname><given-names>A</given-names></name><name><surname>Nyberg</surname><given-names>F</given-names></name><name><surname>Vanfleteren</surname><given-names>LEGW</given-names></name></person-group><article-title>Exacerbation History and Risk of Myocardial Infarction and Pulmonary Embolism in COPD.</article-title>
<source>Chest</source>. <year>2024</year>;<volume>166</volume>:<fpage>1347</fpage>&#x02013;<lpage>59</lpage>. <pub-id pub-id-type="doi">10.1016/j.chest.2024.07.150</pub-id><pub-id pub-id-type="pmid">39094732</pub-id>
</mixed-citation></ref><ref id="R41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>YK</given-names></name><name><surname>Su</surname><given-names>WL</given-names></name><name><surname>Yang</surname><given-names>MC</given-names></name><name><surname>Chen</surname><given-names>SY</given-names></name><name><surname>Wu</surname><given-names>CW</given-names></name><name><surname>Lan</surname><given-names>CC</given-names></name></person-group><article-title>Characterization Associated with the Frequent Severe Exacerbator Phenotype in COPD Patients.</article-title>
<source>Int J Chron Obstruct Pulmon Dis</source>. <year>2021</year>;<volume>16</volume>:<fpage>2475</fpage>&#x02013;<lpage>85</lpage>. <pub-id pub-id-type="doi">10.2147/COPD.S317177</pub-id><pub-id pub-id-type="pmid">34511892</pub-id>
</mixed-citation></ref><ref id="R42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>L</given-names></name><name><surname>Song</surname><given-names>Q</given-names></name><name><surname>Cheng</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><etal/></person-group><article-title>Impact of exacerbation history on future risk and treatment outcomes in chronic obstructive pulmonary disease patients: A prospective cohort study based on Global Initiative for Chronic Obstructive Lung Disease (GOLD) A and B classifications.</article-title>
<source>J Glob Health</source>. <year>2024</year>;<volume>14</volume>:<fpage>04202</fpage>. <pub-id pub-id-type="doi">10.7189/jogh.14.04202</pub-id><pub-id pub-id-type="pmid">39388682</pub-id>
</mixed-citation></ref><ref id="R43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Worth</surname><given-names>H</given-names></name><name><surname>Buhl</surname><given-names>R</given-names></name><name><surname>Cri&#x000e9;e</surname><given-names>CP</given-names></name><name><surname>Kardos</surname><given-names>P</given-names></name><name><surname>Mail&#x000e4;nder</surname><given-names>C</given-names></name><name><surname>Vogelmeier</surname><given-names>C</given-names></name></person-group><article-title>The &#x02018;real-life&#x02019; COPD patient in Germany: The DACCORD study.</article-title>
<source>Respir Med</source>. <year>2016</year>;<volume>111</volume>:<fpage>64</fpage>&#x02013;<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1016/j.rmed.2015.12.010</pub-id><pub-id pub-id-type="pmid">26775251</pub-id>
</mixed-citation></ref><ref id="R44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soriano</surname><given-names>JB</given-names></name></person-group><article-title>Brighter than GOLD.</article-title>
<source>Lancet Respir Med</source>. <year>2018</year>;<volume>6</volume>:<fpage>165</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/S2213-2600(18)30001-8</pub-id><pub-id pub-id-type="pmid">29331312</pub-id>
</mixed-citation></ref><ref id="R45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>D</given-names></name><name><surname>Barnes</surname><given-names>PJ</given-names></name><name><surname>Stockley</surname><given-names>R</given-names></name><name><surname>Lopez Valera</surname><given-names>MV</given-names></name><name><surname>Vogelmeier</surname><given-names>C</given-names></name><name><surname>Agusti</surname><given-names>A</given-names></name></person-group><article-title>Pharmacological treatment of COPD: the devil is always in the detail.</article-title>
<source>Eur Respir J</source>. <year>2018</year>;<volume>51</volume>:<elocation-id>1800263</elocation-id>. <pub-id pub-id-type="doi">10.1183/13993003.00263-2018</pub-id><pub-id pub-id-type="pmid">29674480</pub-id>
</mixed-citation></ref><ref id="R46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cabrera L&#x000f3;pez</surname><given-names>C</given-names></name><name><surname>Casanova Macario</surname><given-names>C</given-names></name><name><surname>Mar&#x000ed;n Trigo</surname><given-names>JM</given-names></name><name><surname>de-Torres</surname><given-names>JP</given-names></name><name><surname>Sicilia Torres</surname><given-names>R</given-names></name><name><surname>Gonz&#x000e1;lez</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Comparison of the 2017 and 2015 Global Initiative for Chronic Obstructive Lung Disease Reports. Impact on Grouping and Outcomes.</article-title>
<source>Am J Respir Crit Care Med</source>. <year>2018</year>;<volume>197</volume>:<fpage>463</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1164/rccm.201707-1363OC</pub-id><pub-id pub-id-type="pmid">29099607</pub-id>
</mixed-citation></ref><ref id="R47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brat</surname><given-names>K</given-names></name><name><surname>Svoboda</surname><given-names>M</given-names></name><name><surname>Zatloukal</surname><given-names>J</given-names></name><name><surname>Plutinsky</surname><given-names>M</given-names></name><name><surname>Volakova</surname><given-names>E</given-names></name><name><surname>Popelkova</surname><given-names>P</given-names></name><etal/></person-group><article-title>Prognostic Properties of the GOLD 2023 Classification System.</article-title>
<source>Int J Chron Obstruct Pulmon Dis</source>. <year>2023</year>;<volume>18</volume>:<fpage>661</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.2147/COPD.S410372</pub-id><pub-id pub-id-type="pmid">37114105</pub-id>
</mixed-citation></ref><ref id="R48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faner</surname><given-names>R</given-names></name><name><surname>Noell</surname><given-names>G</given-names></name><name><surname>Badia</surname><given-names>JR</given-names></name><name><surname>L&#x000f3;pez-Giraldo</surname><given-names>A</given-names></name><name><surname>Bakke</surname><given-names>P</given-names></name><name><surname>Silverman</surname><given-names>EK</given-names></name><etal/></person-group><article-title>Distribution, temporal stability and association with all-cause mortality of the 2017 GOLD groups in the ECLIPSE cohort.</article-title>
<source>Respir Med</source>. <year>2018</year>;<volume>141</volume>:<fpage>14</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.rmed.2018.06.015</pub-id><pub-id pub-id-type="pmid">30053959</pub-id>
</mixed-citation></ref><ref id="R49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lange</surname><given-names>P</given-names></name><name><surname>Marott</surname><given-names>JL</given-names></name><name><surname>Vestbo</surname><given-names>J</given-names></name><name><surname>Olsen</surname><given-names>KR</given-names></name><name><surname>Ingebrigtsen</surname><given-names>TS</given-names></name><name><surname>Dahl</surname><given-names>M</given-names></name><etal/></person-group><article-title>Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population.</article-title>
<source>Am J Respir Crit Care Med</source>. <year>2012</year>;<volume>186</volume>:<fpage>975</fpage>&#x02013;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1164/rccm.201207-1299OC</pub-id><pub-id pub-id-type="pmid">22997207</pub-id>
</mixed-citation></ref><ref id="R50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dusser</surname><given-names>D</given-names></name><name><surname>Wise</surname><given-names>RA</given-names></name><name><surname>Dahl</surname><given-names>R</given-names></name><name><surname>Anzueto</surname><given-names>A</given-names></name><name><surname>Carter</surname><given-names>K</given-names></name><name><surname>Fowler</surname><given-names>A</given-names></name><etal/></person-group><article-title>Differences in outcomes between GOLD groups in patients with COPD in the TIOSPIR(&#x000ae;) trial.</article-title>
<source>Int J Chron Obstruct Pulmon Dis</source>. <year>2016</year>;<volume>11</volume>:<fpage>133</fpage>&#x02013;<lpage>45</lpage>. <pub-id pub-id-type="doi">10.2147/COPD.S97924</pub-id><pub-id pub-id-type="pmid">26855568</pub-id>
</mixed-citation></ref><ref id="R51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>&#x000d6;zden</surname></name><name><surname>Sert&#x000e7;elik</surname><given-names>&#x000dc;</given-names></name><name><surname>Sert&#x000e7;elik</surname><given-names>A</given-names></name><name><surname>Huseynova</surname><given-names>K</given-names></name><name><surname>&#x000d6;ncel</surname><given-names>A</given-names></name><name><surname>Damado&#x0011f;lu</surname><given-names>E</given-names></name><name><surname>&#x000c7;&#x000f6;pl&#x000fc;</surname><given-names>L</given-names></name></person-group><article-title>The Association Between Comorbidities and a High-Risk Status According to COPD GOLD Groups.</article-title>
<source>Acta Medica (Cordoba)</source>. <year>2022</year>;<volume>54</volume>:<fpage>27</fpage>&#x02013;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.32552/2022.ActaMedica.818</pub-id></mixed-citation></ref><ref id="R52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>Y</given-names></name><name><surname>Kim</surname><given-names>YJ</given-names></name><name><surname>Cho</surname><given-names>WK</given-names></name></person-group><article-title>Effect of multiple comorbidities on mortality in chronic obstructive pulmonary disease among Korean population: a nationwide cohort study.</article-title>
<source>BMC Pulm Med</source>. <year>2021</year>;<volume>21</volume>:<fpage>56</fpage>. <pub-id pub-id-type="doi">10.1186/s12890-021-01424-7</pub-id><pub-id pub-id-type="pmid">33573635</pub-id>
</mixed-citation></ref><ref id="R53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greulich</surname><given-names>T</given-names></name><name><surname>Weist</surname><given-names>BJD</given-names></name><name><surname>Koczulla</surname><given-names>AR</given-names></name><name><surname>Janciauskiene</surname><given-names>S</given-names></name><name><surname>Klemmer</surname><given-names>A</given-names></name><name><surname>Lux</surname><given-names>W</given-names></name><etal/></person-group><article-title>Prevalence of comorbidities in COPD patients by disease severity in a German population.</article-title>
<source>Respir Med</source>. <year>2017</year>;<volume>132</volume>:<fpage>132</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.rmed.2017.10.007</pub-id><pub-id pub-id-type="pmid">29229085</pub-id>
</mixed-citation></ref><ref id="R54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santos</surname><given-names>NCD</given-names></name><name><surname>Miravitlles</surname><given-names>M</given-names></name><name><surname>Camelier</surname><given-names>AA</given-names></name><name><surname>Almeida</surname><given-names>VDC</given-names></name><name><surname>Maciel</surname><given-names>RRBT</given-names></name><name><surname>Camelier</surname><given-names>FWR</given-names></name></person-group><article-title>Prevalence and Impact of Comorbidities in Individuals with Chronic Obstructive Pulmonary Disease: A Systematic Review.</article-title>
<source>Tuberc Respir Dis (Seoul)</source>. <year>2022</year>;<volume>85</volume>:<fpage>205</fpage>&#x02013;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.4046/trd.2021.0179</pub-id><pub-id pub-id-type="pmid">35618259</pub-id>
</mixed-citation></ref><ref id="R55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>HL</given-names></name><name><surname>Yin</surname><given-names>SQ</given-names></name><name><surname>Lin</surname><given-names>QY</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>HW</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name></person-group><article-title>Prevalence of comorbidities in chronic obstructive pulmonary disease patients: A meta-analysis.</article-title>
<source>Medicine (Baltimore)</source>. <year>2017</year>;<volume>96</volume>:<elocation-id>e6836</elocation-id>. <pub-id pub-id-type="doi">10.1097/MD.0000000000006836</pub-id><pub-id pub-id-type="pmid">28489768</pub-id>
</mixed-citation></ref><ref id="R56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagorni-Obradovic</surname><given-names>LM</given-names></name><name><surname>Vukovic</surname><given-names>DS</given-names></name></person-group><article-title>The prevalence of COPD co-morbidities in Serbia: results of a national survey.</article-title>
<source>NPJ Prim Care Respir Med</source>. <year>2014</year>;<volume>24</volume>:<fpage>14008</fpage>. <pub-id pub-id-type="doi">10.1038/npjpcrm.2014.8</pub-id><pub-id pub-id-type="pmid">24921714</pub-id>
</mixed-citation></ref><ref id="R57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Axson</surname><given-names>EL</given-names></name><name><surname>Bottle</surname><given-names>A</given-names></name><name><surname>Cowie</surname><given-names>MR</given-names></name><name><surname>Quint</surname><given-names>JK</given-names></name></person-group><article-title>Relationship between heart failure and the risk of acute exacerbation of COPD.</article-title>
<source>Thorax</source>. <year>2021</year>;<volume>76</volume>:<fpage>807</fpage>&#x02013;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1136/thoraxjnl-2020-216390</pub-id><pub-id pub-id-type="pmid">33927022</pub-id>
</mixed-citation></ref><ref id="R58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Figueira Gon&#x000e7;alves</surname><given-names>JM</given-names></name><name><surname>Garc&#x000ed;a Bello</surname><given-names>M&#x000c1;</given-names></name><name><surname>Golpe</surname><given-names>R</given-names></name><name><surname>Alonso Jerez</surname><given-names>JL</given-names></name><name><surname>Garc&#x000ed;a-Talavera</surname><given-names>I</given-names></name></person-group><article-title>Impact of diabetes mellitus on the risk of severe exacerbation in patients with chronic obstructive pulmonary disease.</article-title>
<source>Clin Respir J</source>. <year>2020</year>;<volume>14</volume>:<fpage>1208</fpage>&#x02013;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1111/crj.13255</pub-id><pub-id pub-id-type="pmid">32781483</pub-id>
</mixed-citation></ref><ref id="R59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>TW</given-names></name><name><surname>Huang</surname><given-names>CT</given-names></name><name><surname>Ruan</surname><given-names>SY</given-names></name><name><surname>Tsai</surname><given-names>YJ</given-names></name><name><surname>Lai</surname><given-names>F</given-names></name><name><surname>Yu</surname><given-names>CJ</given-names></name></person-group><article-title>Diabetes mellitus in patients with chronic obstructive pulmonary disease-The impact on mortality.</article-title>
<source>PLoS One</source>. <year>2017</year>;<volume>12</volume>:<elocation-id>e0175794</elocation-id>. <pub-id pub-id-type="doi">10.1371/journal.pone.0175794</pub-id><pub-id pub-id-type="pmid">28410410</pub-id>
</mixed-citation></ref><ref id="R60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Thomas</surname><given-names>J</given-names></name><name><surname>Sadatsafavi</surname><given-names>M</given-names></name><name><surname>FitzGerald</surname><given-names>JM</given-names></name></person-group><article-title>Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.</article-title>
<source>Lancet Respir Med</source>. <year>2015</year>;<volume>3</volume>:<fpage>631</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/S2213-2600(15)00241-6</pub-id><pub-id pub-id-type="pmid">26208998</pub-id>
</mixed-citation></ref><ref id="R61"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rothnie</surname><given-names>KJ</given-names></name><name><surname>Yan</surname><given-names>R</given-names></name><name><surname>Smeeth</surname><given-names>L</given-names></name><name><surname>Quint</surname><given-names>JK</given-names></name></person-group><article-title>Risk of myocardial infarction (MI) and death following MI in people with chronic obstructive pulmonary disease (COPD): a systematic review and meta-analysis.</article-title>
<source>BMJ Open</source>. <year>2015</year>;<volume>5</volume>:<elocation-id>e007824</elocation-id>. <pub-id pub-id-type="doi">10.1136/bmjopen-2015-007824</pub-id><pub-id pub-id-type="pmid">26362660</pub-id>
</mixed-citation></ref><ref id="R62"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Lin</surname><given-names>EP</given-names></name><name><surname>Huang</surname><given-names>LC</given-names></name><name><surname>Li</surname><given-names>CY</given-names></name><name><surname>Shyr</surname><given-names>Y</given-names></name><name><surname>Lai</surname><given-names>CH</given-names></name></person-group><article-title>Mortality of Cardiovascular Events in Patients With COPD and Preceding Hospitalization for Acute Exacerbation.</article-title>
<source>Chest</source>. <year>2020</year>;<volume>158</volume>:<fpage>973</fpage>&#x02013;<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1016/j.chest.2020.02.046</pub-id><pub-id pub-id-type="pmid">32184108</pub-id>
</mixed-citation></ref><ref id="R63"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morgan</surname><given-names>AD</given-names></name><name><surname>Zakeri</surname><given-names>R</given-names></name><name><surname>Quint</surname><given-names>JK</given-names></name></person-group><article-title>Defining the relationship between COPD and CVD: what are the implications for clinical practice?</article-title>
<source>Ther Adv Respir Dis</source>. <year>2018</year>;<volume>12</volume>:<elocation-id>1753465817750524</elocation-id>. <pub-id pub-id-type="doi">10.1177/1753465817750524</pub-id><pub-id pub-id-type="pmid">29355081</pub-id>
</mixed-citation></ref><ref id="R64"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Miguel-D&#x000ed;ez</surname><given-names>J</given-names></name><name><surname>N&#x000fa;&#x000f1;ez Villota</surname><given-names>J</given-names></name><name><surname>Santos P&#x000e9;rez</surname><given-names>S</given-names></name><name><surname>Manito Lorite</surname><given-names>N</given-names></name><name><surname>Alc&#x000e1;zar Navarrete</surname><given-names>B</given-names></name><name><surname>Delgado Jim&#x000e9;nez</surname><given-names>JF</given-names></name><etal/></person-group><article-title>Multidisciplinary Management of Patients With Chronic Obstructive Pulmonary Disease and Cardiovascular Disease.</article-title>
<source>Arch Bronconeumol</source>. <year>2024</year>;<volume>60</volume>:<fpage>226</fpage>&#x02013;<lpage>37</lpage>. <pub-id pub-id-type="doi">10.1016/j.arbres.2024.01.013</pub-id><pub-id pub-id-type="pmid">38383272</pub-id>
</mixed-citation></ref><ref id="R65"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seo</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>Y</given-names></name><name><surname>Jang</surname><given-names>JG</given-names></name><name><surname>Ahn</surname><given-names>JH</given-names></name><name><surname>Ra</surname><given-names>SW</given-names></name><name><surname>Park</surname><given-names>YB</given-names></name><etal/></person-group><article-title>Clinical implications of wheezing in patients with chronic obstructive pulmonary disease.</article-title>
<source>J Thorac Dis</source>. <year>2023</year>;<volume>15</volume>:<fpage>6047</fpage>&#x02013;<lpage>57</lpage>. <pub-id pub-id-type="doi">10.21037/jtd-23-1031</pub-id><pub-id pub-id-type="pmid">38090295</pub-id>
</mixed-citation></ref><ref id="R66"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>A</given-names></name></person-group><article-title>Epidemiological characteristics of asthma-COPD overlap, its association with all-cause mortality, and the mediating role of depressive symptoms: evidence from NHANES 2005-2018.</article-title>
<source>BMC Public Health</source>. <year>2024</year>;<volume>24</volume>:<fpage>1423</fpage>. <pub-id pub-id-type="doi">10.1186/s12889-024-18911-1</pub-id><pub-id pub-id-type="pmid">38807148</pub-id>
</mixed-citation></ref><ref id="R67"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>M&#x000fc;llerova</surname><given-names>H</given-names></name><name><surname>Maselli</surname><given-names>DJ</given-names></name><name><surname>Locantore</surname><given-names>N</given-names></name><name><surname>Vestbo</surname><given-names>J</given-names></name><name><surname>Hurst</surname><given-names>JR</given-names></name><name><surname>Wedzicha</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Hospitalized exacerbations of COPD: risk factors and outcomes in the ECLIPSE cohort.</article-title>
<source>Chest</source>. <year>2015</year>;<volume>147</volume>:<fpage>999</fpage>&#x02013;<lpage>1007</lpage>. <pub-id pub-id-type="doi">10.1378/chest.14-0655</pub-id><pub-id pub-id-type="pmid">25356881</pub-id>
</mixed-citation></ref><ref id="R68"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berry</surname><given-names>CE</given-names></name><name><surname>Wise</surname><given-names>RA</given-names></name></person-group><article-title>Mortality in COPD: causes, risk factors, and prevention.</article-title>
<source>COPD</source>. <year>2010</year>;<volume>7</volume>:<fpage>375</fpage>&#x02013;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.3109/15412555.2010.510160</pub-id><pub-id pub-id-type="pmid">20854053</pub-id>
</mixed-citation></ref><ref id="R69"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilworth</surname><given-names>G</given-names></name><name><surname>Harries</surname><given-names>T</given-names></name><name><surname>Corrigan</surname><given-names>C</given-names></name><name><surname>Thomas</surname><given-names>M</given-names></name><name><surname>White</surname><given-names>P</given-names></name></person-group><article-title>Perceptions of COPD patients of the proposed withdrawal of inhaled corticosteroids prescribed outside guidelines: A qualitative study.</article-title>
<source>Chron Respir Dis</source>. <year>2019</year>;<volume>16</volume>:<elocation-id>1479973119855880</elocation-id>. <pub-id pub-id-type="doi">10.1177/1479973119855880</pub-id><pub-id pub-id-type="pmid">31195812</pub-id>
</mixed-citation></ref><ref id="R70"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chalmers</surname><given-names>JD</given-names></name><name><surname>Miravitlles</surname><given-names>M</given-names></name></person-group><article-title>Withdrawal of inhaled corticosteroids in COPD.</article-title>
<source>Eur Respir J</source>. <year>2020</year>;<volume>56</volume>:<elocation-id>2001778</elocation-id>. <pub-id pub-id-type="doi">10.1183/13993003.01778-2020</pub-id><pub-id pub-id-type="pmid">32646895</pub-id>
</mixed-citation></ref><ref id="R71"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>SL</given-names></name><name><surname>Li</surname><given-names>YR</given-names></name><name><surname>Huang</surname><given-names>N</given-names></name><name><surname>Yu</surname><given-names>CJ</given-names></name><name><surname>Wang</surname><given-names>HC</given-names></name><name><surname>Lin</surname><given-names>MC</given-names></name><etal/></person-group><article-title>Effectiveness of Nationwide COPD Pay-for-Performance Program on COPD Exacerbations in Taiwan.</article-title>
<source>Int J Chron Obstruct Pulmon Dis</source>. <year>2021</year>;<volume>16</volume>:<fpage>2869</fpage>&#x02013;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.2147/COPD.S329454</pub-id><pub-id pub-id-type="pmid">34703221</pub-id>
</mixed-citation></ref><ref id="R72"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>WY</given-names></name><name><surname>Hsiao</surname><given-names>CH</given-names></name><name><surname>Chen</surname><given-names>YC</given-names></name><name><surname>Ho</surname><given-names>CH</given-names></name><name><surname>Wang</surname><given-names>JJ</given-names></name><name><surname>Hsing</surname><given-names>CH</given-names></name><etal/></person-group><article-title>Cisplatin Nephrotoxicity Might Have a Sex Difference. An analysis Based on Women&#x02019;s Sex Hormone Changes.</article-title>
<source>J Cancer</source>. <year>2017</year>;<volume>8</volume>:<fpage>3939</fpage>&#x02013;<lpage>44</lpage>. <pub-id pub-id-type="doi">10.7150/jca.20083</pub-id><pub-id pub-id-type="pmid">29187868</pub-id>
</mixed-citation></ref></ref-list></back></article>